RLD,RS,TE_code,active_ingredients,company,dosageform_route,drug_class,drug_name,marketing_status,review_priority,strength,use,rare,hereditary,medical_area,specific,gender,year
TBD,No,None,necitumumab,ELI LILLY CO,"INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL",,Portrazza,Prescription,N/A,800MG/50ML,To treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer,no,no,cancer,Lung,adults,11/24/2015
No,No,None,elotuzumab,BRISTOL MYERS SQUIBB,INJECTABLE;INJECTION,,Empliciti,Prescription,N/A; Orphan,300MG,"
			",no,no,cancer,Myeloma,adults,11/30/2015
No,No,None,elotuzumab,BRISTOL MYERS SQUIBB,INJECTABLE;INJECTION,,Empliciti,Prescription,N/A; Orphan,400MG,"
			",no,no,cancer,Myeloma,adults,11/30/2015
No,No,None,sebelipase alfa,ALEXION PHARM,INJECTABLE;INJECTION,,Kanuma,Prescription,N/A; Orphan,20MG/10ML,To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiency,yes,no,digestive,lipids and cholesterol metabolism,adults,12/8/2015
Yes,Yes,None,alectinib,HOFFMANN-LA ROCHE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Alecensa,Prescription,PRIORITY; Orphan,EQ 150MG BASE,To treat ALK-positive lung cancer,no,no,cancer,Lung,adults,12/11/2015
Yes,Yes,None,sugammadex,ORGANON SUB MERCK,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Bridion,Prescription,PRIORITY,EQ 500MG BASE/5ML (EQ 100MG BASE/ML),"
			",no,no,nervous system,neurology,adults,12/15/2015
Yes,No,None,sugammadex,ORGANON SUB MERCK,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Bridion,Prescription,PRIORITY,EQ 200MG BASE/2ML (EQ 100MG BASE/ML),"
			",no,no,nervous system,nervous system,adults,12/15/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,0.2MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,Yes,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,0.4MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,0.6MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,0.8MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,1MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,1.2MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,1.4MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,selexipag,ACTELION,TABLET;ORAL,Type 1 - New Molecular Entity,Uptravi,Prescription,STANDARD; Orphan,1.6MG,To treat pulmonary arterial hypertension,no,no,cardiovascular,lung blood pressure,adults,12/21/2015
Yes,No,None,lesinurad,IRONWOOD PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Zurampic,Discontinued,STANDARD,200MG,To treat high blood uric acid levels associated with gout,no,no,nephrology,gout,adults,12/22/2015
Yes,No,None,daclatasvir,BRISTOL-MYERS SQUIBB,TABLET;ORAL,Type 1 - New Molecular Entity,Daklinza,Discontinued,PRIORITY,EQ 30MG BASE,To treat chronic hepatitis C virus (HCV) genotype 3 infections,no,no,hepatitis C,liver,adults,7/24/2015
Yes,No,None,daclatasvir,BRISTOL-MYERS SQUIBB,TABLET;ORAL,Type 1 - New Molecular Entity,Daklinza,Discontinued,PRIORITY,EQ 60MG BASE,To treat chronic hepatitis C virus (HCV) genotype 3 infections,no,no,hepatitis C,liver,adults,7/24/2015
Yes,No,None,daclatasvir,BRISTOL-MYERS SQUIBB,TABLET;ORAL,Type 1 - New Molecular Entity,Daklinza,Discontinued,PRIORITY,EQ 90MG BASE,To treat chronic hepatitis C virus (HCV) genotype 3 infections,no,no,hepatitis C,liver,adults,7/24/2015
Yes,Yes,None,flibanserin,SPROUT PHARMS,TABLET;ORAL,Type 1 - New Molecular Entity,Addyi,Prescription,STANDARD,100MG,"To treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women",no,no,mental health,mental health,women,8/18/2015
TBD,No,None,evolocumab,AMGEN INC,INJECTABLE;INJECTION,,Repatha,Prescription,N/A; Orphan,140MG/ML,"
			",no,no,cardiovascular,heart,adults,8/27/2015
Yes,No,None,edoxaban,DAIICHI SANKYO INC,TABLET;ORAL,Type 1 - New Molecular Entity,Savaysa,Prescription,STANDARD,EQ 15MG BASE,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem,no,no,cardiovascular,blood clots,adults,1/8/2015
Yes,No,None,edoxaban,DAIICHI SANKYO INC,TABLET;ORAL,Type 1 - New Molecular Entity,Savaysa,Prescription,STANDARD,EQ 30MG BASE,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem,no,no,cardiovascular,blood clots,adults,1/8/2015
Yes,Yes,None,edoxaban,DAIICHI SANKYO INC,TABLET;ORAL,Type 1 - New Molecular Entity,Savaysa,Prescription,STANDARD,EQ 60MG BASE,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem,no,no,cardiovascular,blood clots,adults,1/8/2015
Yes,Yes,None,elbasvir and grazoprevir,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Zepatier,Prescription,PRIORITY,50MG;100MG,To treat patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.,no,no,hepatitis C,liver,adults,1/28/2016
Yes,Yes,None,plecanatide,SALIX,TABLET;ORAL,Type 1 - New Molecular Entity,Trulance,Prescription,STANDARD,3MG,To treat Chronic Idiopathic Constipation (CIC) in adult patients.,no,no,digestive,constipation,adults,1/19/2017
Yes,Yes,None,lutetium Lu 177 dotatate,AAA USA INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Lutathera,Prescription,PRIORITY; Orphan,10mCi/ML,To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).,no,no,cancer,digestive,adults,1/26/2018
No,No,None,,EVOLUS INC,INJECTABLE;INJECTION,,Jeuveau,Prescription,N/A,100 UNITS,,no,no,cosmetic,eyebrows,adults,2/1/2019
Yes,No,None,avapritinib,BLUEPRINT MEDICINES,TABLET;ORAL,Type 1 - New Molecular Entity,Ayvakit,Prescription,PRIORITY; Orphan,100MG,To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST),no,no,cancer,gastrointestinal,adults,1/9/2020
Yes,No,None,avapritinib,BLUEPRINT MEDICINES,TABLET;ORAL,Type 1 - New Molecular Entity,Ayvakit,Prescription,PRIORITY; Orphan,200MG,To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST),no,no,cancer,gastrointestinal,adults,1/9/2020
Yes,Yes,None,avapritinib,BLUEPRINT MEDICINES,TABLET;ORAL,Type 1 - New Molecular Entity,Ayvakit,Prescription,PRIORITY; Orphan,300MG,To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST),no,no,cancer,gastrointestinal,adults,1/9/2020
Yes,No,None,vericiguat,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Verquvo,Prescription,PRIORITY,2.5MG,To treat chronic heart failure,no,no,cardiovascular,heart,adults,1/19/2021
Yes,No,None,vericiguat,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Verquvo,Prescription,PRIORITY,5MG,To treat chronic heart failure,no,no,cardiovascular,heart,adults,1/19/2021
Yes,Yes,None,vericiguat,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Verquvo,Prescription,PRIORITY,10MG,To treat chronic heart failure,no,no,cardiovascular,heart,adults,1/19/2021
Yes,Yes,None,cabotegravir and rilpivirine,VIIV HLTHCARE,"SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR",Type 1 - New Molecular Entity and Type 4 - New Combination,Cabenuva,Prescription,PRIORITY,400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),To treat HIV,no,no,HIV,HIV,adults,1/21/2021
Yes,Yes,None,cabotegravir and rilpivirine,VIIV HLTHCARE,"SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR",Type 1 - New Molecular Entity and Type 4 - New Combination,Cabenuva,Prescription,PRIORITY,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),To treat HIV,no,no,HIV,HIV,adults,1/21/2021
Yes,Yes,None,voclosporin,AURINIA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Lupkynis,Prescription,PRIORITY,7.9MG,To treat lupus nephritis,no,no,nephrology,autoimmune,adults,1/22/2021
Yes,Yes,None,tepotinib,EMD SERONO INC,TABLET;ORAL,Type 1 - New Molecular Entity,Tepmetko,Prescription,PRIORITY; Orphan,EQ 225MG BASE,To treat non-small cell lung cancer,no,no,cancer,Lung,adults,2/3/2021
Yes,Yes,None,umbralisib,TG THERAPS,TABLET;ORAL,Type 1 - New Molecular Entity,Ukoniq,Prescription,PRIORITY; Orphan,EQ 200MG BASE,For the treatment of certain patients with marginal zone lymphoma and follicular lymphoma,no,no,cancer,blood,adults,2/5/2021
No,No,None,evinacumab-dgnb,REGENERON PHARMACEUTICALS,SOLUTION; INJECTION,,Evkeeza,Prescription,N/A; Orphan,345MG/2.3ML,For the treatment of homozygous familial hypercholesterolemia,no,no,cardiovascular,high cholesterol,adults,2/11/2021
No,No,None,evinacumab-dgnb,REGENERON PHARMACEUTICALS,SOLUTION; INJECTION,,Evkeeza,Prescription,N/A; Orphan,1200MG/8ML,For the treatment of homozygous familial hypercholesterolemia,no,no,cardiovascular,high cholesterol,adults,2/11/2021
Yes,Yes,None,trilacicilib,G1 THERAP,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Cosela,Prescription,PRIORITY,EQ 300MG BASE/VIAL,To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer,no,no,cancer,Lung,adults,2/12/2021
Yes,Yes,None,casimersen,SAREPTA THERAPS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Amondys 45,Prescription,PRIORITY; Orphan,100MG/2ML (50MG/ML),For the treatment of Duchenne muscular dystrophy,no,no,muscular,muscular,adults,2/25/2021
Yes,Yes,None,fosdenopterin,ORIGIN,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Nulibry,Prescription,PRIORITY; Orphan,EQ 9.5MG BASE/VIAL,To treat patients with the rare genetic disease molybdenum cofactor deficiency Type A,no,no,muscular,muscular,infants andchildren,2/26/2021
Yes,Yes,None,melphalan flufenamide,ONCOPEPTIDES AB,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Pepaxto,Prescription,PRIORITY; Orphan,20MG/VIAL,For the treatment of certain patients with relapsed or refractory multiple myeloma,no,no,cancer,blood,adults,2/26/2021
TBD,No,None,serdexmethylphenidate and,COMMCAVE THERAPEUTICS SA,CAPSULE;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Azstarys,Prescription,STANDARD,26.1MG/5.2MG,For the treatment of Attention Deficit Hyperactivity,no,no,mental health,mental health,children and adults,3/3/2021
TBD,No,None,serdexmethylphenidate and,COMMCAVE THERAPEUTICS SA,CAPSULE;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Azstarys,Prescription,STANDARD,39.2MG/7.8MG,For the treatment of Attention Deficit Hyperactivity,no,no,mental health,mental health,adults,3/3/2021
TBD,No,None,serdexmethylphenidate and,COMMCAVE THERAPEUTICS SA,CAPSULE;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Azstarys,Prescription,STANDARD,52.3MG/10.4MG,For the treatment of Attention Deficit Hyperactivity,no,no,mental health,mental health,adults,3/3/2021
TBD,No,None,tivozanib,AVEO PHARMACEUTICALS INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Fotivda,Prescription,STANDARD,0.89MG,To treat patients with renal cell carcinoma,no,no,cancer,nephrology,adults,3/10/2021
TBD,No,None,tivozanib,AVEO PHARMACEUTICALS INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Fotivda,Prescription,STANDARD,1.34MG,To treat patients with renal cell carcinoma,no,no,cancer,nephrology,adults,3/10/2021
TBD,No,None,teprotumumab-trbw,HORIZON THERAPEUTICS IRELAND,INJECTABLE;INJECTION,,Tepezza,Prescription,N/A; Orphan,500MG,To treat Thyroid eye disease,no,no,neurology,eye,adults,1/21/2020
Yes,Yes,None,tazemetostat,EPIZYME INC,TABLET;ORAL,Type 1 - New Molecular Entity,Tazverik,Prescription,PRIORITY; Orphan,EQ 200MG BASE,To treat epithelioid sarcoma,no,no,cancer,skin,adults,1/23/2020
Yes,No,None,"
			",BRAINTREE LABS,FOR SOLUTION;ORAL,Type 1 - New Molecular Entity,Pizensy,Discontinued,STANDARD,10GM,To treat chronic idiopathic constipation (CIC) in adults,no,no,digestive,constipation,adults,2/12/2020
TBD,No,,"
			",BRAINTREE LABS,SOLUTION;ORAL,Type 1 - New Molecular Entity,Pizensy,Prescription,STANDARD,20G,To treat chronic idiopathic constipation (CIC) in adults,no,no,digestive,constipation,adults,2/12/2020
Yes,Yes,None,"
			",ESPERION THERAPS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Nexletol,Prescription,STANDARD,180MG,To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C,yes,yes,cardiovascular,cholesterol,adults,2/21/2020
No,No,None,eptinezumab-jjmr,"Lundbeck Seattle BioPharmaceuticals, Inc.",INJECTABLE;INJECTION,,Vyepti,Prescription,N/A,100MG/ML,For the preventive treatment of migraine in adults,no,no,neurology,migraine,adults,2/21/2020
Yes,Yes,None,amisulpride,ACACIA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Barhemsys,Prescription,STANDARD,5MG/2ML (2.5MG/ML),To help prevent nausea and vomiting after surgery,no,no,other,nausea,adults,2/26/2020
Yes,Yes,None,amisulpride,ACACIA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Barhemsys,Prescription,STANDARD,10MG/4ML (2.5MG/ML),To help prevent nausea and vomiting after surgery,no,no,other,nausea,adults,2/26/2020
Yes,Yes,None,rimegepant,BIOHAVEN PHARM,"TABLET, ORALLY DISINTEGRATING;ORAL",Type 1 - New Molecular Entity,Nurtec ODT,Prescription,PRIORITY,EQ 75MG BASE,To treat migraine,no,no,neurology,migraine,adults,2/27/2020
No,No,None,isatuximab,SANOFI AVENTIS US,INJECTABLE;INJECTION,,Sarclisa,Prescription,N/A; Orphan,100MG/5ML (20MG/ML),To treat multiple myloma,no,no,cancer,blood,adults,3/2/2020
No,No,None,isatuximab,SANOFI AVENTIS US,INJECTABLE;INJECTION,,Sarclisa,Prescription,N/A; Orphan,500MG/25ML (20MG/ML),To treat multiple myloma,no,no,cancer,blood,adults,3/2/2020
Yes,No,None,osilodrostat,RECORDATI RARE,TABLET;ORAL,Type 1 - New Molecular Entity,Isturisa,Prescription,STANDARD; Orphan,EQ 1MG BASE,To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease,no,no,endocrinology,Cushing disease,adults,3/6/2020
Yes,No,None,osilodrostat,RECORDATI RARE,TABLET;ORAL,Type 1 - New Molecular Entity,Isturisa,Prescription,STANDARD; Orphan,EQ 5MG BASE,To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease,no,no,endocrinology,Cushing disease,adults,3/6/2020
Yes,Yes,None,osilodrostat,RECORDATI RARE,TABLET;ORAL,Type 1 - New Molecular Entity,Isturisa,Prescription,STANDARD; Orphan,EQ 10MG BASE,To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease,no,no,endocrinology,Cushing disease,adults,3/6/2020
Yes,No,None,ozanimod,CELGENE INTL,CAPSULE;ORAL,Type 1 - New Molecular Entity,Zeposia,Prescription,STANDARD,0.23MG,To treat relapsing forms of multiple sclerosis,no,no,immune disease,multiple sclerosis,adults,3/25/2020
Yes,No,None,ozanimod,CELGENE INTL,CAPSULE;ORAL,Type 1 - New Molecular Entity,Zeposia,Prescription,STANDARD,0.46MG,To treat relapsing forms of multiple sclerosis,no,no,immune disease,multiple sclerosis,adults,3/25/2020
Yes,Yes,None,ozanimod,CELGENE INTL,CAPSULE;ORAL,Type 1 - New Molecular Entity,Zeposia,Prescription,STANDARD,0.92MG,To treat relapsing forms of multiple sclerosis,no,no,immune disease,multiple sclerosis,adults,3/25/2020
Yes,No,None,selumetinib,ASTRAZENECA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Koselugo,Prescription,PRIORITY; Orphan,EQ 10MG BASE,"To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves",yes,yes,cancer,nervous system,adults,4/10/2020
Yes,Yes,None,selumetinib,ASTRAZENECA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Koselugo,Prescription,PRIORITY; Orphan,EQ 25MG BASE,"To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves",yes,yes,cancer,nervous system,adults,4/10/2020
Yes,No,None,tucatinib,SEAGEN,TABLET;ORAL,Type 1 - New Molecular Entity,Tukysa,Prescription,PRIORITY; Orphan,50MG,To treat advanced unresectable or metastatic HER2-positive breast cancer,no,no,cancer,breast,female,4/17/2020
Yes,Yes,None,tucatinib,SEAGEN,TABLET;ORAL,Type 1 - New Molecular Entity,Tukysa,Prescription,PRIORITY; Orphan,150MG,To treat advanced unresectable or metastatic HER2-positive breast cancer,no,no,cancer,breast,adults,4/17/2020
Yes,No,None,pemigatinib,INCYTE CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Pemazyre,Prescription,PRIORITY; Orphan,4.5MG,"To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts",no,no,cancer,digestive,adults,4/17/2020
Yes,No,None,pemigatinib,INCYTE CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Pemazyre,Prescription,PRIORITY; Orphan,9MG,"To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts",no,no,cancer,digestive,adults,4/17/2020
Yes,Yes,None,pemigatinib,INCYTE CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Pemazyre,Prescription,PRIORITY; Orphan,13.5MG,"To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts",no,no,cancer,digestive,adults,4/17/2020
TBD,No,None,sacituzumab govitecan-hziy,IMMUNOMEDICS INC,INJECTABLE;INJECTION,,Trodelvy,Prescription,N/A,180MG,To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease,no,no,cancer,breast,female,4/22/2020
Yes,No,None,opicapone,NEUROCRINE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ongentys,Prescription,STANDARD,25MG,To treat patients with Parkinson’s disease experiencing “off” episodes,no,no,muscular,Parkinson’s disease,adults,4/24/2020
Yes,Yes,None,opicapone,NEUROCRINE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ongentys,Prescription,STANDARD,50MG,To treat patients with Parkinson’s disease experiencing “off” episodes,no,no,muscular,Parkinson’s disease,adults,4/24/2020
Yes,No,None,capmatinib,NOVARTIS PHARM,TABLET;ORAL,Type 1 - New Molecular Entity,Tabrecta,Prescription,PRIORITY; Orphan,EQ 150MG BASE,To treat patients with non small cell lung cancer,no,no,cancer,Lung,adults,5/6/2020
Yes,Yes,None,capmatinib,NOVARTIS PHARM,TABLET;ORAL,Type 1 - New Molecular Entity,Tabrecta,Prescription,PRIORITY; Orphan,EQ 200MG BASE,To treat patients with non small cell lung cancer,no,no,cancer,Lung,adults,5/6/2020
Yes,No,None,,LOXO ONCOLOGY INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Retevmo,Prescription,PRIORITY; Orphan,40MG,To treat lung and thyroid cancers,no,no,cancer,Lung and thyroid,adults,5/8/2020
Yes,Yes,None,,LOXO ONCOLOGY INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Retevmo,Prescription,PRIORITY; Orphan,80MG,To treat lung and thyroid cancers,no,no,cancer,Lung and thyroid,adults,5/8/2020
Yes,Yes,None,ripretinib,DECIPHERA PHARMS,TABLET;ORAL,Type 1 - New Molecular Entity,Qinlock,Prescription,PRIORITY; Orphan,50MG,To treat advanced gastrointestinal-stromal tumors,no,no,cancer,digestive,adults,5/15/2020
Yes,Yes,None,fluoroestradiol F18,ZIONEXA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Cerianna,Prescription,STANDARD,50ML (4-100mCi/ML),Diagnostic imaging agent for certain patients with breast cancer,no,no,cancer,cancer location,adults,5/20/2020
Yes,Yes,None,artesunate,AMIVAS,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Artesunate,Prescription,PRIORITY; Orphan,110MG/VIAL,To treat severe malaria,no,no,vector-borne diseases,malaria,adults,5/26/2020
Yes,No,None,abametapir,DR REDDYS LABS SA,LOTION;TOPICAL,Type 1 - New Molecular Entity,Xeglyze,Discontinued,STANDARD,0.74%,To treat head lice,no,no,vector-borne diseases,lice,adults,7/24/2020
Yes,Yes,None,flortaucipir F18,AVID RADIOPHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Tauvid,Prescription,PRIORITY,30ML (8.1-51mCi/ML),Diagnostic agent for patients with Alzheimer’s disease,no,no,mental health,Alzheimer’s disease,adults,5/28/2020
Yes,Yes,None,flortaucipir F18,AVID RADIOPHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Tauvid,Prescription,PRIORITY,50ML (8.1-51mCi/ML),Diagnostic agent for patients with Alzheimer’s disease,no,no,mental health,Alzheimer’s disease,adults,5/28/2020
No,No,None,inebilizumab-cdon,VIELA BIO,INJECTABLE;INJECTION,,Uplizna,Prescription,N/A; Orphan,100MG/10ML,To treat neuromyelitis optica spectrum disorder,no,no,neurology,eye,adults,6/11/2020
Yes,Yes,None,lurbinectedin,JAZZ,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Zepzelca,Prescription,PRIORITY; Orphan,4MG/VIAL,To treat metastatic small cell lung cancer,no,no,cancer,Lung,adults,6/15/2020
Yes,Yes,None,triheptanoin,ULTRAGENYX PHARM INC,LIQUID;ORAL,Type 1 - New Molecular Entity,Dojolvi,Prescription,STANDARD; Orphan,100% w/w,To treat molecularly long-chain fatty acid oxidation disorders,no,no,digestive,fatty acid,adults,6/30/2020
Yes,Yes,None,,ACACIA,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Byfavo,Prescription,STANDARD,EQ 20MG BASE/VIAL,For sedation,no,no,nervous system,sedation,adults,7/2/2020
Yes,Yes,None,,VIIV HLTHCARE,"TABLET, EXTENDED RELEASE;ORAL",Type 1 - New Molecular Entity,Rukobia,Prescription,PRIORITY,EQ 600MG BASE,"
			",no,no,HIV,HIV,adults,7/2/2020
Yes,Yes,None,decitabine and cedazuridine,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Inqovi,Prescription,PRIORITY; Orphan,100MG;35MG,To treat adult patients with myelodysplastic syndromes,no,no,cancer,blood,adults,7/7/2020
No,No,None,tafasitamab-cxix,MORPHOSYS US INC,INJECTABLE;INJECTION,,Monjuvi,Prescription,N/A; Orphan,12MG/KG,To treat relapsed or refractory diffuse large B-cell lymphoma,no,no,cancer,blood,adults,7/31/2020
No,No,None,belantamab mafodotin-blmf,GLAXOSMITHKLINE,INJECTABLE;INTRAVENOUS,,Blenrep,Prescription,N/A; Orphan,2.5MG/KG,To treat multiple myeloma,no,no,cancer,blood,adults,8/5/2020
Yes,No,None,nifurtimox,BAYER HEALTHCARE,TABLET;ORAL,Type 1 - New Molecular Entity,Lampit,Prescription,PRIORITY; Orphan,30MG,To treat Chagas disease in certain pediatric patients younger than age 18,no,no,insect bite,Chagas disease,children,8/6/2020
Yes,Yes,None,nifurtimox,BAYER HEALTHCARE,TABLET;ORAL,Type 1 - New Molecular Entity,Lampit,Prescription,PRIORITY; Orphan,120MG,To treat Chagas disease in certain pediatric patients younger than age 18,no,no,insect bite,Chagas disease,children,8/6/2020
Yes,Yes,None,risdiplam,GENENTECH INC,FOR SOLUTION;ORAL,Type 1 - New Molecular Entity,Evrysdi,Prescription,PRIORITY; Orphan,0.75MG/ML,To treat spinal muscular atrophy,no,no,muscular,muscular,adults,8/7/2020
Yes,Yes,None,oliceridine,TREVENA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Olinvyk,Prescription,STANDARD,1MG/ML (1MG/ML),To manage acute pain in certain adults,no,no,muscular,muscular,adults,8/7/2020
Yes,Yes,None,oliceridine,TREVENA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Olinvyk,Prescription,STANDARD,2MG/2ML (1MG/ML),To manage acute pain in certain adults,no,no,muscular,muscular,adults,8/7/2020
Yes,Yes,None,oliceridine,TREVENA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Olinvyk,Prescription,STANDARD,30MG/30ML (1MG/ML),To manage acute pain in certain adults,no,no,muscular,muscular,adults,8/7/2020
Yes,Yes,None,viltolarsen,NIPPON SHINYAKU,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Viltepso,Prescription,PRIORITY; Orphan,250MG/5ML (50MG/ML),To treat Duchenne muscular dystrophy,yes,yes,muscular,Duchenne muscular dystrophy,male,8/12/2020
No,No,None,satralizumab-mwge,GENENTECH,INJECTABLE;INJECTION,,Enspryng,Prescription,N/A; Orphan,120MG/ML,To treat neuromyelitis optica spectrum disorder,no,no,neurology,neurology,adults,8/14/2020
Yes,No,None,clascoterone,CASSIOPEA SPA,CREAM;TOPICAL,Type 1 - New Molecular Entity,Winlevi,Discontinued,STANDARD,1%,To treat acne,no,no,cosmetic,acne,children,8/26/2020
No,No,None,somapacitan-beco,NOVO NORDISK INC,SOLUTION;SUBCUTANEOUS,,Sogroya,Prescription,N/A,10MG/1.5ML,Growth hormone,no,no,endocrinology,growth hormone,adults,8/28/2020
Yes,Yes,None,copper Cu 64 dotatate injection,RADIOMEDIX,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Detectnet,Prescription,PRIORITY; Orphan,4mL (1mCi/ML),To help detect certain types of neuroendocrine tumors,no,no,cancer,endocrine location,adults,9/3/2020
Yes,Yes,None,pralsetinib,BLUEPRINT MEDICINES,CAPSULE;ORAL,Type 1 - New Molecular Entity,Gavreto,Prescription,PRIORITY; Orphan,100MG,To treat non-small lung cancer,no,no,cancer,Lung,children and adults,9/4/2020
No,No,None,"atoltivimab, maftivimab, and odesivimab-ebgn",REGENERON PHARMACEUTICALS,SOLUTION; INJECTION,,Inmazeb,Prescription,N/A; Orphan,16.7MG/1ML,To treat ebola virus,no,no,ebola virus,ebola virus,adults,10/14/2020
Yes,Yes,None,remdesivir,GILEAD SCIENCES INC,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Veklury,Prescription,PRIORITY,100MG/VIAL,To treat COVID-19,no,no,COVID-19,COVID-19,adults,10/22/2020
Yes,Yes,None,remdesivir,GILEAD SCIENCES INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Veklury,Prescription,PRIORITY,100MG/20ML (5MG/ML),To treat COVID-19,no,no,COVID-19,COVID-19,adults,10/22/2020
Yes,No,None,lonafarnib,EIGER BIOPHARMS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Zokinvy,Prescription,PRIORITY; Orphan,50MG,To ,yes,no,Hutchinson-Gilford Progeria Syndrome;,Hutchinson-Gilford Progeria Syndrome;,infant and children,11/20/2020
Yes,Yes,None,lonafarnib,EIGER BIOPHARMS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Zokinvy,Prescription,PRIORITY; Orphan,75MG,To ,yes,no,Hutchinson-Gilford Progeria Syndrome;,Hutchinson-Gilford Progeria Syndrome;,infant and children,11/20/2020
Yes,Yes,None,lumasiran,ALNYLAM PHARMS INC,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Oxlumo,Prescription,PRIORITY; Orphan,EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE),To treat hyperoxaluria type 1,no,yes,nephrology,nephrology,adults,11/23/2020
Yes,Yes,None,setmelanotide,RHYTHM,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Imcivree,Prescription,PRIORITY; Orphan,EQ 10MG/ML BASE (EQ 10MG/ML BASE),"To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age",no,yes,metabolic,obesity,children and adults,11/25/2020
No,No,None,naxitamab-gqgk,Y-MABS THERAPEUTICS INC,SOLUTION;INTRAVENOUS,,Danyelza,Prescription,N/A; Orphan,40MG/10ML,To treat high-risk refractory or relapsed neuroblastoma,no,no,cancer,neuroblastoma,children and adults,11/25/2020
Yes,Yes,None,Gallium 68 PSMA-11,UNIV CA LOS ANGELES,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Gallium 68 PSMA-11,Prescription,STANDARD,30ML (0.5-5MCI/ML),For detection and localization of prostate cancer,no,no,cancer,cancer location,male,12/1/2020
Yes,No,None,berotralstat,BIOCRYST,CAPSULE;ORAL,Type 1 - New Molecular Entity,Orladeyo,Prescription,STANDARD; Orphan,EQ 110MG BASE,To treat patients with hereditary angioedema,yes,yes,Hereditary angioedema,Hereditary angioedema,children and adults,12/3/2020
Yes,Yes,None,berotralstat,BIOCRYST,CAPSULE;ORAL,Type 1 - New Molecular Entity,Orladeyo,Prescription,STANDARD; Orphan,EQ 150MG BASE,To treat patients with hereditary angioedema,yes,yes,Hereditary angioedema,Hereditary angioedema,children and adults,12/3/2020
Yes,Yes,None,tirbanibulin,ALMIRALL,OINTMENT;TOPICAL,Type 1 - New Molecular Entity,Klisyri,Prescription,STANDARD,1%,To treat actinic Keratosis of the face or scalp,no,no,skin,skin,adults,12/14/2020
TBD,No,None,margetuximab (anti-HER2 mAb,MACROGENICS INC,INJECTABLE;INJECTION,,Margenza,Prescription,N/A,250MG/10ML(25MG/ML),To treat HER2+ breast cancer,no,no,cancer,breast,adults,12/16/2020
Yes,Yes,None,relugolix,MYOVANT SCIENCES,TABLET;ORAL,Type 1 - New Molecular Entity,Orgovyx,Prescription,PRIORITY,120MG,To treat advanced prostate cancer,no,no,cancer,prostate,male,12/18/2020
No,No,None,"
			",RIDGEBACK BIOTHERAPEUTICS,POWDER;IV (INFUSION),,Ebanga,Prescription,N/A; Orphan,400MG/VIAL,To treat ebola,no,no,ebola virus,ebola virus,children and adults,12/21/2020
Yes,Yes,None,vibegron,UROVANT,TABLET;ORAL,Type 1 - New Molecular Entity,Gemtesa,Prescription,STANDARD,75MG,To treat overactive bladder,no,no,nephrology,nephrology,adults,12/23/2020
No,No,None,caplacizumab-yhdp,ABLYNX NV,INJECTABLE;INJECTION,,Cablivi,Prescription,N/A; Orphan,11MG/VIAL,To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP),no,no,immune disease,immunotherapy,adults,2/6/2019
Yes,Yes,None,,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Egaten,Prescription,PRIORITY; Orphan,250MG,"To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”",no,no,vector-borne diseases,worms,children and adults,2/13/2019
Yes,Yes,None,brexanolone,SAGE THERAP,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Zulresso,Prescription,PRIORITY,100MG/20ML (5MG/ML),To treat postpartum depression (PPD) in adult women,no,no,mental health,mental health,female,3/19/2019
Yes,No,None,solriamfetol,JAZZ,TABLET;ORAL,Type 1 - New Molecular Entity,Sunosi,Prescription,STANDARD,EQ 75MG BASE,To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea,no,no,other,sleep,adults,3/20/2019
Yes,Yes,None,solriamfetol,JAZZ,TABLET;ORAL,Type 1 - New Molecular Entity,Sunosi,Prescription,STANDARD,EQ 150MG BASE,To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea,no,no,other,sleep,adults,3/20/2019
Yes,No,None,siponimod,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Mayzent,Prescription,PRIORITY,EQ 0.25MG BASE,To treat adults with relapsing forms of multiple sclerosis,no,no,immune disease,multiple sclerosis,adults,3/26/2019
Yes,Yes,None,siponimod,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Mayzent,Prescription,PRIORITY,EQ 2MG BASE,To treat adults with relapsing forms of multiple sclerosis,no,no,immune disease,multiple sclerosis,adults,3/26/2019
No,No,None,romosozumab-aqqg,AMGEN INC,INJECTABLE;INJECTION,,Evenity,Prescription,N/A,105MG/1.17ML,To treat osteoporosis in postmenopausal women at high risk of fracture,no,no,immune disease,osteoporosis ,female,4/9/2019
Yes,No,None,erdafitinib,JANSSEN BIOTECH,TABLET;ORAL,Type 1 - New Molecular Entity,Balversa,Prescription,PRIORITY,3MG,To treat adult patients with locally advanced or metastatic bladder cancer,no,no,cancer,nephrology,adults,4/12/2019
Yes,No,None,erdafitinib,JANSSEN BIOTECH,TABLET;ORAL,Type 1 - New Molecular Entity,Balversa,Prescription,PRIORITY,4MG,To treat adult patients with locally advanced or metastatic bladder cancer,no,no,cancer,nephrology,adults,4/12/2019
Yes,Yes,None,erdafitinib,JANSSEN BIOTECH,TABLET;ORAL,Type 1 - New Molecular Entity,Balversa,Prescription,PRIORITY,5MG,To treat adult patients with locally advanced or metastatic bladder cancer,no,no,cancer,nephrology,adults,4/12/2019
No,No,None,risankizumab-rzaa,ABBVIE INC,INJECTABLE;INJECTION,,Skyrizi ,Prescription,N/A,75MG/0.83ML,To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,no,no,skin,skin,adults,4/23/2019
Yes,Yes,None,tafamidis meglumine,FOLDRX PHARMS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vyndaqel,Prescription,PRIORITY; Orphan,20MG,To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults,no,yes,cardiovascular,cardiovascular,adults,5/3/2019
Yes,No,None,alpelisib,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Piqray,Prescription,PRIORITY,50MG,To treat breast cancer,no,no,cancer,breast,female,5/24/2019
Yes,No,None,alpelisib,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Piqray,Prescription,PRIORITY,150MG,To treat breast cancer,no,no,cancer,breast,female,5/24/2019
Yes,Yes,None,alpelisib,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Piqray,Prescription,PRIORITY,200MG,To treat breast cancer,no,no,cancer,breast,female,5/24/2019
No,No,None,polatuzumab vedotin-piiq,GENENTECH,POWDER;INTRAVENOUS,,Polivy,Prescription,N/A; Orphan,140MG/VIAL,To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma,no,no,cancer,blood,adults,6/10/2019
No,No,None,polatuzumab vedotin-piiq,GENENTECH,POWDER;INTRAVENOUS,,Polivy,Prescription,N/A; Orphan,30MG/VIAL,To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma,no,no,cancer,blood,adults,6/10/2019
Yes,Yes,None,bremelanotide,PALATIN TECHNOLOGIES,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Vyleesi,Prescription,STANDARD,EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML),To treat hypoactive sexual desire disorder in premenopausal women.,no,no,mental health,mental health,female,6/21/2018
Yes,Yes,None,selinexor,KARYOPHARM THERAPS,TABLET;ORAL,Type 1 - New Molecular Entity,Xpovio,Prescription,PRIORITY; Orphan,20MG,To treat adult patients with relapsed or refractory multiple myeloma (RRMM),no,no,cancer,bone marrow,adults,7/3/2019
Yes,Yes,None,"imipenem, cilastatin and relebactam",MSD MERCK CO,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Recarbrio,Prescription,PRIORITY,EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL,To treat complicated urinary tract and complicated intra-abdominal infections,no,no,nephrology,nephrology,adults,7/16/2019
Yes,No,None,ferric maltol,SHIELD TX,CAPSULE;ORAL,Type 1 - New Molecular Entity,Accrufer,Discontinued,STANDARD,30MG IRON,To treat,no,no,other,iron deficiency,adults,7/25/2019
Yes,Yes,None,darolutamide,BAYER HEALTHCARE,TABLET;ORAL,Type 1 - New Molecular Entity,Nubeqa,Prescription,PRIORITY,300MG,To treat adult patients with non-metastatic castration resistant prostate cancer,no,no,cancer,prostate,male,7/30/2019
Yes,Yes,None,pexidartinib,DAIICHI SANKYO INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Turalio,Prescription,PRIORITY; Orphan,EQ 200MG BASE,To treat adult patients with symptomatic tenosynovial giant cell tumor,yes,no,cancer,lungs,adults,8/2/2019
Yes,Yes,None,,MYLAN IRELAND LTD,TABLET;ORAL,Type 1 - New Molecular Entity,pretomanid,Prescription,PRIORITY; Orphan,200MG,For treatment-resistant forms of tuberculosis that affects the lungs,yes,no,pulmonary,tuberculosis,adults and children,8/14/2019
Yes,No,None,entrectinib,GENENTECH INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Rozlytrek,Prescription,PRIORITY; Orphan,100MG,"
			",yes,no,cancer,lung,adults,8/15/2019
Yes,Yes,None,entrectinib,GENENTECH INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Rozlytrek,Prescription,PRIORITY; Orphan,200MG,"
			",yes,no,cancer,lung,adults,8/15/2019
Yes,Yes,None,fedratinib,IMPACT,CAPSULE;ORAL,Type 1 - New Molecular Entity,Inrebic,Prescription,PRIORITY; Orphan,EQ 100MG BASE,To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis,yes,no,cancer,blood,adults,8/16/2019
Yes,Yes,None,upadacitinib,ABBVIE INC,"TABLET, EXTENDED RELEASE;ORAL",Type 1 - New Molecular Entity,Rinvoq,Prescription,PRIORITY,15MG,To treat adults with moderately to severely active rheumatoid arthritis,no,no,immune disease,rheumatoid arthritis,adults,8/16/2019
Yes,Yes,None,lefamulin,NABRIVA,TABLET;ORAL,Type 1 - New Molecular Entity,Xenleta,Prescription,PRIORITY,EQ 600MG BASE,To treat adults with community-acquired bacterial pneumonia,no,no,other,pneumonia,adults,8/19/2019
Yes,Yes,None,"
			",UIHC PET IMAGING,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Ga-68-DOTATOC,Prescription,STANDARD; Orphan,0.5-4mCi/ML,"
			",no,no,cancer,cancer location,adults,8/21/2019
Yes,No,None,istradefylline,KYOWA KIRIN,TABLET;ORAL,Type 1 - New Molecular Entity,Nourianz,Prescription,STANDARD,20MG,To treat ,no,no,nervous system,Parkinson’s disease,adults,8/27/2019
Yes,Yes,None,istradefylline,KYOWA KIRIN,TABLET;ORAL,Type 1 - New Molecular Entity,Nourianz,Prescription,STANDARD,40MG,To treat ,no,no,nervous system,Parkinson’s disease,adults,8/27/2019
Yes,No,None,tenapanor,ARDELYX INC,TABLET;ORAL,Type 1 - New Molecular Entity,Ibsrela,Discontinued,STANDARD,EQ 50MG BASE,To treat irritable bowel syndrome with constipation in adults.,no,no,digestive,constipation,adults,9/12/2019
Yes,Yes,None,trifarotene,GALDERMA LABS LP,CREAM;TOPICAL,Type 1 - New Molecular Entity,Aklief,Prescription,STANDARD,0.005%,"
			",no,no,skin,acne,children and adults,10/4/2019
No,No,None,brolucizumab–dbll,NOVARTIS PHARMS CORP,INJECTABLE; INTRAVITREAL,,Beovu,Prescription,N/A,6MG/0.05ML,Treatment of wet age-related macular degeneration,no,no,muscular,eye,adults,10/7/2019
Yes,Yes,None,afamelanotide,CLIVUNEL INC,IMPLANT;SUBCUTANEOUS,Type 1 - New Molecular Entity,Scenesse,Prescription,PRIORITY; Orphan,16MG,To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria,no,no,skin,skin,adults,10/8/2019
Yes,No,None,lasmiditan,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Reyvow,Prescription,STANDARD,50MG,"
			",no,no,neurology,neurology,adults,10/11/2019
Yes,Yes,None,lasmiditan,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Reyvow,Prescription,STANDARD,100MG,"
			",no,no,neurology,neurology,adults,10/11/2019
Yes,No,None,lasmiditan,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Reyvow,Prescription,STANDARD,200MG,"
			",no,no,neurology,neurology,adults,10/11/2019
Yes,Yes,None,elexacaftor/ivacaftor/tezacaftor,VERTEX PHARMS INC,"TABLET, TABLET;ORAL",Type 1 - New Molecular Entity,Trikafta,Prescription,PRIORITY; Orphan,"100MG,75MG,50MG;N/A,150MG,N/A","
			",no,yes,pulmonary,cystic fibrosis,adults,10/21/2019
Yes,Yes,None,air polymer-type A,GISKIT,FOAM;INTRAUTERINE,Type 1 - New Molecular Entity,ExEm Foam,Prescription,STANDARD,10ML, diagnostic agent used to assess fallopian tube patency (openness),no,no,fertility,imaging,female,11/7/2019
No,No,None,luspatercept–aamt,CELGENE CORP,POWDER;SUBCUTANEOUS,,Reblozyl,Prescription,N/A; Orphan,25MG/VIAL,"
			",no,yes,cardiovascular,anemia,adults,11/8/2019
No,No,None,luspatercept–aamt,CELGENE CORP,POWDER;SUBCUTANEOUS,,Reblozyl,Prescription,N/A; Orphan,75MG/VIAL,"
			",no,yes,cardiovascular,anemia,adults,11/8/2019
Yes,Yes,None,zanubrutinib,BEIGENE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Brukinsa,Prescription,PRIORITY; Orphan,80MG,"
			",no,no,cancer,lymph node,adults,11/14/2019
Yes,Yes,None,cefiderocol,SHIONOGI INC,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Fetroja,Prescription,PRIORITY,EQ 1GM BASE/VIAL,To treat patients with complicated urinary tract infections who have limited or no alternative treatment options,yes,no,nephrology,UTI,adults,11/14/2019
No,No,None,crizanlizumab-tmca,NOVARTIS PHARMS CORP,INJECTABLE; INJECTION,,Adakveo,Prescription,N/A; Orphan,100MG/10ML,To treat patients with painful complication of sickle cell disease,yes,yes,cardiovascular, anemia,children and adults,11/15/2019
Yes,Yes,None,givosiran,ALNYLAM PHARMS INC,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Givlaari,Prescription,PRIORITY; Orphan,EQ 189MG BASE/ML (EQ 189MG BASE/ML),"To treat acute hepatic porphyria, a rare blood disorder",yes,yes,hepatic,acute hepatic porphyria,adults,11/20/2019
Yes,No,None,cenobamate,SK LIFE,TABLET;ORAL,Type 1 - New Molecular Entity,Xcopri,Prescription,STANDARD,12.5MG,To treat partial onset seizures,no,no,muscular,seizures,adults,11/21/2019
Yes,No,None,cenobamate,SK LIFE,TABLET;ORAL,Type 1 - New Molecular Entity,Xcopri,Prescription,STANDARD,25MG,To treat partial onset seizures,no,no,muscular,seizures,adults,11/21/2019
Yes,No,None,cenobamate,SK LIFE,TABLET;ORAL,Type 1 - New Molecular Entity,Xcopri,Prescription,STANDARD,50MG,To treat partial onset seizures,no,no,muscular,seizures,adults,11/21/2019
Yes,No,None,cenobamate,SK LIFE,TABLET;ORAL,Type 1 - New Molecular Entity,Xcopri,Prescription,STANDARD,100MG,To treat partial onset seizures,no,no,muscular,seizures,adults,11/21/2019
Yes,No,None,cenobamate,SK LIFE,TABLET;ORAL,Type 1 - New Molecular Entity,Xcopri,Prescription,STANDARD,150MG,To treat partial onset seizures,no,no,muscular,seizures,adults,11/21/2019
Yes,Yes,None,cenobamate,SK LIFE,TABLET;ORAL,Type 1 - New Molecular Entity,Xcopri,Prescription,STANDARD,200MG,To treat partial onset seizures,no,no,muscular,seizures,adults,11/21/2019
Yes,Yes,None,voxelotor,GLOBAL BLOOD THERAPS,TABLET;ORAL,Type 1 - New Molecular Entity,Oxbryta,Prescription,PRIORITY; Orphan,500MG,To treat sickle cell disease,no,yes,cardiovascular,anemia,adults,11/25/2019
Yes,Yes,None,golodirsen,SAREPTA THERAPS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Vyondys 53,Prescription,PRIORITY; Orphan,100MG/2ML (50MG/ML),To treat certain patients with Duchenne muscular dystrophy,yes,yes,muscular,Duchenne muscular dystrophy,male,12/12/2019
No,No,None,enfortumab vedotin-ejfv,ASTELLAS,INJECTABLE;INJECTION,,Padcev,Prescription,N/A,20MG/VIAL,To treat refractory bladder cancer,no,no,cancer,nephrology,adults,12/18/2019
No,No,None,enfortumab vedotin-ejfv,ASTELLAS,INJECTABLE;INJECTION,,Padcev,Prescription,N/A,30MG/VIAL,To treat refractory bladder cancer,no,no,cancer,nephrology,adults,12/18/2019
Yes,Yes,None,Brilliant Blue G Ophthalmic Solution,DUTCH OPHTHALMIC,SOLUTION;OPHTHALMIC,Type 1 - New Molecular Entity,TissueBlue,Prescription,PRIORITY; Orphan,0.025%,Dye used in eye surgery,no,no,muscular,imaging,adults,12/20/2019
Yes,Yes,None,lumateperone tosylate,INTRA-CELLULAR,CAPSULE;ORAL,Type 1 - New Molecular Entity,Caplyta,Prescription,STANDARD,EQ 42MG BASE,To treat schizophrenia,no,no,mental health,schizophrenia,adults,12/20/2019
Yes,No,None,lemborexant,EISAI INC,TABLET;ORAL,Type 1 - New Molecular Entity,Dayvigo,Prescription,STANDARD,5MG,To treat insomnia,no,no,other,sleep,adults,12/20/2019
Yes,Yes,None,lemborexant,EISAI INC,TABLET;ORAL,Type 1 - New Molecular Entity,Dayvigo,Prescription,STANDARD,10MG,To treat insomnia,no,no,other,sleep,adults,12/20/2019
TBD,No,None,fam-trastuzumab deruxtecan-nxki,DAIICHI SANKYO,INJECTABLE;INJECTION,,Enhertu,Prescription,N/A,100MG,To treat metastatic breast cancer,no,no,cancer,breast,female,12/20/2019
Yes,No,None,ubrogepant,ALLERGAN,TABLET;ORAL,Type 1 - New Molecular Entity,Ubrelvy,Prescription,STANDARD,50MG,to treat acute treatment of migraine with or without aura in adults,no,no,neurology,migraine,adults,12/23/2019
Yes,Yes,None,ubrogepant,ALLERGAN,TABLET;ORAL,Type 1 - New Molecular Entity,Ubrelvy,Prescription,STANDARD,100MG,to treat acute treatment of migraine with or without aura in adults,yes,no,HIV,HIV,adults,12/23/2019
Yes,Yes,None,"bictegravir, embitcitabine, tenofovir alafenamide",GILEAD SCIENCES INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Biktarvy,Prescription,PRIORITY,EQ 50MG BASE;200MG;EQ 25MG BASE,To treat infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen,yes,no,HIV,HIV,adults,2/7/2018
Yes,Yes,None,tezacaftor; ivacaftor,VERTEX PHARMS INC,"TABLET, TABLET;ORAL",Type 1 - New Molecular Entity,Symdeko,Prescription,PRIORITY; Orphan,"150MG,N/A;150MG, 100MG",To treat cystic fibrosis in patients age 12 years and older,no,yes,pulmonary,cystic fibrosis,adults and children,2/12/2018
Yes,No,None,tezacaftor; ivacaftor,VERTEX PHARMS INC,"TABLET, TABLET;ORAL",Type 1 - New Molecular Entity,Symdeko,Prescription,PRIORITY; Orphan,"75MG,N/A;75MG, 50MG",To treat cystic fibrosis in patients age 12 years and older,no,yes,pulmonary,cystic fibrosis,adults and children,2/12/2018
Yes,Yes,None,apalutamide,JANSSEN BIOTECH,TABLET;ORAL,Type 1 - New Molecular Entity,Erleada,Prescription,PRIORITY,60MG,To treat a certain type of prostate cancer using novel clinical trial endpoint,no,no,cancer,prostate,male,2/14/2018
No,No,None,ibalizumab-uiyk,TAIMED BIOLOGICS USA,INJECTABLE;INJECTION,,Trogarzo,Prescription,N/A; Orphan,150MG/ML,To treat HIV patients who have limited treatment options,no,yes,HIV,HIV,adults,3/6/2018
No,No,None,tildrakizumab,SUN PHARMA GLOBAL,INJECTABLE;INJECTION,,Ilumya,Prescription,N/A,100MG/1ML,To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy,no,no,immune disease,plaque psoriasis,adults,3/20/2018
Yes,No,None,fostamatinib,RIGEL PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Tavalisse,Prescription,STANDARD; Orphan,EQ 100MG BASE,To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP),no,no,immune disease,immune thrombocytopenia ,adults,4/17/2018
Yes,Yes,None,fostamatinib,RIGEL PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Tavalisse,Prescription,STANDARD; Orphan,EQ 150MG BASE,To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP),no,no,immune disease,immune thrombocytopenia ,adults,4/17/2018
Yes,Yes,None,moxidectin,MDGH,TABLET;ORAL,Type 1 - New Molecular Entity,Moxidectin,Prescription,PRIORITY; Orphan,2MG,To treat onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older,no,no,vector-borne diseases,insect bite,adults and children,6/13/2018
TBD,No,None,burosumab-twza,ULTRAGENYX PHARM INC,INJECTABLE;INJECTION,,Crysvita,Prescription,N/A; Orphan,10MG/ML,"To treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets",yes,yes,cardiovascular,x-linked hypophosphatemia,adults and children,4/17/2018
Yes,Yes,None,fosnetupitant and palonosetron,HELSINN HLTHCARE,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Akynzeo,Prescription,STANDARD,EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL,To prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy,no,no,cancer,nausea,adults,4/19/2018
Yes,Yes,None,fosnetupitant and palonosetron,HELSINN HLTHCARE,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Akynzeo,Prescription,STANDARD,EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML),To prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy,no,no,cancer,nausea,adults,4/19/2018
Yes,Yes,None,lofexidine hydrochloride,USWM,TABLET;ORAL,Type 1 - New Molecular Entity,Lucemyra,Prescription,PRIORITY,EQ 0.18MG BASE,For the non-opioid treatment for management of opioid withdrawal symptoms in adults,no,no,mental,drug treatment,adults,5/16/2018
No,No,None,erenumab-aooe,AMGEN INC,INJECTABLE;INJECTION,,Aimovig,Prescription,N/A,70MG/ML,For the preventive treatment for migraine,no,no,neurology,migraine,adults,5/17/2018
Yes,No,None,sodium zirconium cyclosilicate,ASTRAZENECA,FOR SUSPENSION;ORAL,Type 1 - New Molecular Entity,Lokelma,Prescription,STANDARD,5GM/PACKET,To treat hyperkalemia,no,no,cardiovascular,cardiovascular,adults,5/18/2018
Yes,Yes,None,sodium zirconium cyclosilicate,ASTRAZENECA,FOR SUSPENSION;ORAL,Type 1 - New Molecular Entity,Lokelma,Prescription,STANDARD,10GM/PACKET,To treat hyperkalemia,no,no,cardiovascular,cardiovascular,adults,5/18/2018
Yes,Yes,None,avatrombopag,AKARX INC,TABLET;ORAL,Type 1 - New Molecular Entity,Doptelet,Prescription,PRIORITY; Orphan,EQ 20MG BASE,To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure,no,no,cardiovascular,cardiovascular,adults,5/21/2018
No,No,None,pegvaliase-pqpz,BIOMARIN PHARM,INJECTABLE;INJECTION,,Palynziq,Prescription,N/A; Orphan,2.5MG/O.5ML,To treat adults with a rare and serious genetic disease known as phenylketonuria (PKU),yes,yes,metabolic,phenylketonuria ,adults,5/24/2018
No,No,None,pegvaliase-pqpz,BIOMARIN PHARM,INJECTABLE;INJECTION,,Palynziq,Prescription,N/A; Orphan,10MG/0.5ML,To treat adults with a rare and serious genetic disease known as phenylketonuria (PKU),yes,yes,metabolic,phenylketonuria ,adults,5/24/2018
No,No,None,pegvaliase-pqpz,BIOMARIN PHARM,INJECTABLE;INJECTION,,Palynziq,Prescription,N/A; Orphan,20MG/ML,To treat adults with a rare and serious genetic disease known as phenylketonuria (PKU),yes,yes,metabolic,phenylketonuria ,adults,5/24/2018
Yes,Yes,None,baricitinib,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Olumiant,Prescription,STANDARD,2MG,To treat moderately to severely active rheumatoid arthritis,no,no,immune disease,rheumatoid arthritis,adults,5/31/2018
Yes,No,None,baricitinib,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Olumiant,Prescription,STANDARD,1MG,To treat moderately to severely active rheumatoid arthritis,no,no,immune disease,rheumatoid arthritis,adults,5/31/2018
Yes,Yes,None,cannabidiol,GW RES LTD,SOLUTION;ORAL,Type 1 - New Molecular Entity,Epidioloex,Prescription,PRIORITY; Orphan,100MG/ML,"To treat rare, severe forms of epilepsy",no,no,nervous system,seizures,adults,6/25/2018
Yes,Yes,None,plazomicin,CIPLA USA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Zemdri,Prescription,PRIORITY,EQ 500MG BASE/10ML (EQ 50MG BASE/ML),To treat adults with complicated urinary tract infections,no,no,nephrology,UTI,adults,6/25/2018
Yes,Yes,None,binimetinib,ARRAY BIOPHARMA INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Mektovi,Prescription,STANDARD; Orphan,15MG,To treat unresectable or metastatic melanoma,no,no,cancer,skin,adults,6/27/2018
Yes,No,None,encorafenib,ARRAY BIOPHARMA INC,CAPSULE;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Braftovi,Discontinued,STANDARD; Orphan,50MG,To treat unresectable or metastatic melanoma,no,no,cancer,skin,adults,6/27/2018
Yes,Yes,None,encorafenib,ARRAY BIOPHARMA INC,CAPSULE;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Braftovi,Prescription,STANDARD; Orphan,75MG,To treat unresectable or metastatic melanoma,no,no,cancer,skin,adults,6/27/2018
Yes,Yes,None,tecovirimat,SIGA TECHNOLOGIES,CAPSULE;ORAL,Type 1 - New Molecular Entity,TPOXX,Prescription,PRIORITY; Orphan,200MG,To treat smallpox,no,no,smallpox,smallpox,adults,7/13/2018
Yes,Yes,None,ivosidenib,AGIOS PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Tibsovo,Prescription,PRIORITY; Orphan,250MG,To treat patients with relapsed or refractory acute myeloid leukemia,no,no,cancer,blood,adults,7/20/2018
Yes,Yes,None,,GLAXOSMITHKLINE,TABLET;ORAL,Type 1 - New Molecular Entity,Krintafel,Prescription,PRIORITY; Orphan,EQ 150MG BASE,For the radical cure (prevention of relapse) of Plasmodium vivax malaria,no,no,vector-borne diseases,malaria,adults,7/20/2018
Yes,No,None,elagolix sodium,ABBVIE INC,TABLET;ORAL,Type 1 - New Molecular Entity,Orilissa,Prescription,PRIORITY,EQ 150MG BASE,For the management of moderate to severe pain associated with endometriosis,no,no,gynecology,endometriosis,female,7/23/2018
Yes,Yes,None,elagolix sodium,ABBVIE INC,TABLET;ORAL,Type 1 - New Molecular Entity,Orilissa,Prescription,PRIORITY,EQ 200MG BASE,For the management of moderate to severe pain associated with endometriosis,no,no,gynecology,endometriosis,female,7/23/2018
Yes,Yes,None,fish oil triglycerides,FRESENIUS KABI USA,EMULSION;INTRAVENOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Omegaven,Prescription,PRIORITY; Orphan,5GM/50ML (0.1GM/ML),As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis,no,no,digestive,intestinal failure ,children,7/27/2018
Yes,Yes,None,fish oil triglycerides,FRESENIUS KABI USA,EMULSION;INTRAVENOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Omegaven,Prescription,PRIORITY; Orphan,10GM/100ML (0.1GM/ML),As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis,no,no,digestive,intestinal failure ,children,7/27/2018
Yes,Yes,None,lusutrombopag,SHIONOGI INC,TABLET;ORAL,Type 1 - New Molecular Entity,Mulpleta,Prescription,PRIORITY,3MG,To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure,no,no,cardiovascular,blood clots,adults,7/31/2018
TBD,No,None,mogamulizumab-kpkc,KYOWA KIRIN,INJECTABLE;INJECTION,,Poteligeo,Prescription,N/A; Orphan,20MG/5ML,To treat two rare types of non-Hodgkin lymphoma,no,no,cancer,blood,adults,8/8/2018
Yes,Yes,None,patisiran,ALNYLAM PHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Onpattro,Prescription,PRIORITY; Orphan,EQ 10MG BASE/5ML (EQ 2MG BASE/ML),To treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients,no,yes,nephrology,nephrology,adults,8/10/2018
Yes,Yes,None,segesterone acetate and ethinyl estradiol vaginal system,THERAPEUTICSMD INC,RING;VAGINAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Annovera,Prescription,STANDARD,0.013MG/24HR;0.15MG/24HR,New vaginal ring used to prevent pregnancy for an entire year,no,no,gynecology,gynecology,female,8/10/2018
Yes,Yes,None,migalastat,AMICUS THERAPS US,CAPSULE;ORAL,Type 1 - New Molecular Entity,Galafold,Prescription,PRIORITY; Orphan,EQ 123MG BASE,To treat treat adults with Fabry disease.,no,yes,metabolic,fatty acid,adults,8/10/2018
Yes,No,None,stiripentol,BIOCODEX SA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Diacomit,Prescription,PRIORITY; Orphan,250MG,To treat seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam,no,no,muscular,seizures,children and adults,8/20/2018
Yes,Yes,None,stiripentol,BIOCODEX SA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Diacomit,Prescription,PRIORITY; Orphan,500MG,To treat seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam,no,no,muscular,seizures,children and adults,8/20/2018
No,No,None,cenegermin-bkbj,DOMPE FARMACEUTICI,SOLUTION;OPHTHALMIC,,xervate,Prescription,N/A; Orphan,0.002%(20MCG/ML),To treat neurotrophic keratitis,yes,no,neurology,eye,adults,8/22/2018
No,No,None,lanadelumab,DYAX CORP.,INJECTABLE;INJECTION,,Takhzyro,Prescription,N/A; Orphan,300MG/ML(150MG/ML),To treat types I and II hereditary angioedema,no,yes,skin,hereditary angioedema ,children and adults,8/23/2018
Yes,Yes,None,eravacycline,TETRAPHASE PHARMS,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Xerava,Prescription,PRIORITY,EQ 50MG BASE/VIAL,To treat complicated intra-abdominal infections in patients 18 years of age and older,no,no,digestive,infection,adults,8/27/2018
Yes,Yes,None,eravacycline,TETRAPHASE PHARMS,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Xerava,Prescription,PRIORITY,EQ 100MG BASE/VIAL,To treat complicated intra-abdominal infections in patients 18 years of age and older,no,no,digestive,infection,adults,8/27/2018
Yes,Yes,None,doravirine,MSD MERCK CO,TABLET;ORAL,Type 1 - New Molecular Entity,Pifeltro,Prescription,STANDARD,100MG,To treat HIV-1 infection in adult patients,no,yes,HIV,HIV,adults,8/30/2018
No,No,None,moxetumomab pasudotox-tdfk,INNATE PHARMA,INJECTABLE;INJECTION,,Lumoxiti,Prescription,N/A; Orphan,1MG/VIAL,To treat hairy cell leukemia,yes,no,cancer,blood,adults,9/13/2018
No,No,None,fremanezumab-vfrm,TEVA PHARMS USA,INJECTABLE;INJECTION,,Ajovy,Prescription,N/A,150MG/ML,For the preventive treatment of migraine in adults,no,no,neurology,migraine,adults,9/14/2018
Yes,No,None,talazoparib,PFIZER,CAPSULE;ORAL,Type 1 - New Molecular Entity,Talzenna,Prescription,PRIORITY,EQ 0.25MG BASE,To treat locally advanced or metastatic breast cancer patients with a germline BRCA mutation.,no,no,cancer,breast,female,10/16/2018
Yes,Yes,None,talazoparib,PFIZER,CAPSULE;ORAL,Type 1 - New Molecular Entity,Talzenna,Prescription,PRIORITY,EQ 1MG BASE,To treat locally advanced or metastatic breast cancer patients with a germline BRCA mutation.,no,no,cancer,breast,female,10/16/2018
Yes,No,None,duvelisib,SECURA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Copiktra,Prescription,PRIORITY; Orphan,15MG,"To treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma",no,no,cancer,blood,adults,9/24/2018
Yes,Yes,None,duvelisib,SECURA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Copiktra,Prescription,PRIORITY; Orphan,25MG,"To treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma",no,no,cancer,blood,adults,9/24/2018
No,No,None,galcanezumab-gnlm,ELI LILLY AND CO,INJECTABLE;INJECTION,,Emgality,Prescription,N/A,120MG/ML,For the preventive treatment of migraine in adults,no,no,neurology,migraine,adults,9/27/2018
No,No,None,cemiplimab-rwlc,REGENERON PHARMACEUTICALS,INJECTABLE;INTRAVENOUS,,Libtayo,Prescription,N/A,350MG,To treat cutaneous squamous cell carcinoma (CSCC),no,no,cancer,lung,adults,9/27/2019
Yes,No,None,sarecycline,ALMIRALL,TABLET;ORAL,Type 1 - New Molecular Entity,Seysara,Prescription,STANDARD,EQ 60MG BASE,To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older,no,no,cancer,skin,adults,9/28/2018
Yes,No,None,sarecycline,ALMIRALL,TABLET;ORAL,Type 1 - New Molecular Entity,Seysara,Prescription,STANDARD,EQ 100MG BASE,To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older,no,no,skin,acne,children and adults,10/1/2018
Yes,Yes,None,sarecycline,ALMIRALL,TABLET;ORAL,Type 1 - New Molecular Entity,Seysara,Prescription,STANDARD,EQ 150MG BASE,To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older,no,no,skin,acne,children and adults,10/1/2018
Yes,Yes,None,omadacycline,PARATEK PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Nuzyra,Prescription,PRIORITY,EQ 150MG BASE,To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections,no,no,skin,acne,children and adults,10/1/2018
No,No,None,elapegademase-lvlr,LEADIANT BIOSCI INC,INJECTABLE;INJECTION,,Revcovi,Prescription,N/A; Orphan,1.6MG/ML,To treat Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID),no,no,vector-borne diseases,pneumonia,adults,10/2/2018
Yes,Yes,None,inotersen,AKCEA THERAPS,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Tegsedi,Prescription,PRIORITY; Orphan,EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML),To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,yes,yes,immune disease,ADA-SCID,adults,10/5/2018
Yes,No,None,baloxavir marboxil,GENENTECH INC,TABLET;ORAL,Type 1 - New Molecular Entity,Xofluza,Prescription,PRIORITY,20MG,To treat acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours.,yes,yes,nephrology,nephrology,adults,10/5/2018
Yes,Yes,None,baloxavir marboxil,GENENTECH INC,TABLET;ORAL,Type 1 - New Molecular Entity,Xofluza,Prescription,PRIORITY,40MG,To treat acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours.,no,no,vector-borne diseases,influenza,adults,10/24/2018
Yes,No,None,lorlatinib,PFIZER,TABLET;ORAL,Type 1 - New Molecular Entity,Lorbrena,Prescription,PRIORITY; Orphan,25MG,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer,no,no,vector-borne diseases,influenza,adults,10/24/2018
Yes,Yes,None,lorlatinib,PFIZER,TABLET;ORAL,Type 1 - New Molecular Entity,Lorbrena,Prescription,PRIORITY; Orphan,100MG,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer,no,no,cancer,lung,adults,11/2/2018
Yes,Yes,None,revefenacin,MYLAN IRELAND LTD,SOLUTION;INHALATION,Type 1 - New Molecular Entity,Yupelri,Prescription,STANDARD,175MCG/3ML,To treat patients with chronic obstructive pulmonary disease (COPD),no,no,cancer,lung,adults,11/2/2018
Yes,Yes,None,rifamycin,REDHILL,"TABLET, DELAYED RELEASE;ORAL",Type 1 - New Molecular Entity,Aemcolo,Prescription,PRIORITY,EQ 194MG BASE,To treat travelers’ diarrhea,no,no,pulmonary,lung,adults,11/9/2018
No,No,None,emapalumab-lzsgemapalumab-lzsg,NOVIMMUNE S.A.,INJECTABLE;INJECTION,,Gamifant,Prescription,N/A; Orphan,10MG/2ML,To treat primary hemophagocytic lymphohistiocytosis (HLH),no,no,digestive,digestive,adults,11/16/2018
No,No,None,emapalumab-lzsgemapalumab-lzsg,NOVIMMUNE S.A.,INJECTABLE;INJECTION,,Gamifant,Prescription,N/A; Orphan,50MG/10ML,To treat primary hemophagocytic lymphohistiocytosis (HLH),yes,no,cardiovascular,blood,adults,11/20/2018
No,No,None,emapalumab-lzsgemapalumab-lzsg,NOVIMMUNE S.A.,INJECTABLE;INJECTION,,Gamifant,Prescription,N/A; Orphan,100MG/20ML,To treat primary hemophagocytic lymphohistiocytosis (HLH),yes,no,cardiovascular,blood,adults,11/20/2018
Yes,No,None,glasdegib,PFIZER,TABLET;ORAL,Type 1 - New Molecular Entity,Daurismo,Prescription,PRIORITY; Orphan,EQ 25MG BASE,To treat newly-diagnosed acute myeloid leukemia (AML) in adult patients,yes,no,cardiovascular,blood,adults,11/20/2018
Yes,Yes,None,glasdegib,PFIZER,TABLET;ORAL,Type 1 - New Molecular Entity,Daurismo,Prescription,PRIORITY; Orphan,EQ 100MG BASE,To treat newly-diagnosed acute myeloid leukemia (AML) in adult patients,no,no,cancer,blood,adults,11/21/2018
Yes,No,None,larotrectinib,BAYER HLTHCARE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vitrakvi,Prescription,PRIORITY; Orphan,EQ 25MG BASE,To treat patients whose cancers have a specific genetic feature (biomarker),no,no,cancer,blood,adults,11/21/2018
Yes,Yes,None,larotrectinib,BAYER HLTHCARE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vitrakvi,Prescription,PRIORITY; Orphan,EQ 100MG BASE,To treat patients whose cancers have a specific genetic feature (biomarker),no,no,pulmonary,lung,adults,11/26/2018
Yes,Yes,None,amifampridine,CATALYST PHARMS,TABLET;ORAL,Type 1 - New Molecular Entity,Firdapse,Prescription,PRIORITY; Orphan,EQ 10MG BASE,To treat  Lambert-Eaton myasthenic syndrome (LEMS) in adults,no,no,pulmonary,lung,adults,11/26/2018
Yes,Yes,None,gilteritinib,ASTELLAS,TABLET;ORAL,Type 1 - New Molecular Entity,Xospata,Prescription,PRIORITY; Orphan,EQ 40MG BASE,To treat patients who have relapsed or refractory acute myeloid leukemia (AML),yes,no,neurology,neurology,adults,11/28/2028
Yes,No,None,prucalopride,TAKEDA PHARMS USA,TABLET;ORAL,Type 1 - New Molecular Entity,Motegrity,Prescription,STANDARD,EQ 1MG BASE,To treat chronic idiopathic constipation,no,no,cancer,blood,adults,11/28/2018
Yes,Yes,None,prucalopride,TAKEDA PHARMS USA,TABLET;ORAL,Type 1 - New Molecular Entity,Motegrity,Prescription,STANDARD,EQ 2MG BASE,To treat chronic idiopathic constipation,no,no,digestive,constipation,adults,12/14/2018
No,No,None,calaspargase pegol-mknl,SERVIER PHARMA LLC,INJECTABLE;INTRAVENOUS,,Asparlas,Prescription,N/A; Orphan,3750UNITS/5ML,To treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years,no,no,digestive,constipation,adults,12/14/2018
No,No,None,tagraxofusp-erzs,STEMLINE THERAPEUTICS INC,SOLUTION;INJECTION,,Elzonris,Prescription,N/A; Orphan,1000MCG,To treat blastic plasmacytoid dendritic cell neoplasm (BPDCN),no,no,cancer,blood,"infant, children and adult",12/20/2018
No,No,None,ravulizumab,ALEXION PHARM,INJECTABLE;INJECTION,,Ultomiris,Prescription,N/A; Orphan,300MG/30ML(10MG/ML),To treat paroxysmal nocturnal hemoglobinuria (PNH),no,no,cancer,nervous system,children and adults,12/21/2018
Yes,Yes,None,etelcalcetide,KAI PHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Parsabiv,Prescription,STANDARD,2.5MG/0.5ML (2.5MG/0.5ML),To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis,yes,no,cardiovascular,blood,adults,12/21/2018
Yes,Yes,None,etelcalcetide,KAI PHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Parsabiv,Prescription,STANDARD,5MG/ML (5MG/ML),To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis,no,no,nephrology,nephrology,adults,2/7/2017
Yes,Yes,None,etelcalcetide,KAI PHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Parsabiv,Prescription,STANDARD,10MG/2ML (5MG/ML),To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis,no,no,nephrology,nephrology,adults,2/7/2017
Yes,No,None,deflazacort,PTC THERAP,TABLET;ORAL,Type 1 - New Molecular Entity,Emflaza,Prescription,PRIORITY; Orphan,6MG,To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),no,no,nephrology,nephrology,adults,2/7/2017
Yes,No,None,deflazacort,PTC THERAP,TABLET;ORAL,Type 1 - New Molecular Entity,Emflaza,Prescription,PRIORITY; Orphan,18MG,To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),yes,yes,muscular,Duchenne muscular dystrophy,children and adults,2/9/2017
Yes,No,None,deflazacort,PTC THERAP,TABLET;ORAL,Type 1 - New Molecular Entity,Emflaza,Prescription,PRIORITY; Orphan,30MG,To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),yes,yes,muscular,Duchenne muscular dystrophy,children and adults,2/9/2017
Yes,Yes,None,deflazacort,PTC THERAP,TABLET;ORAL,Type 1 - New Molecular Entity,Emflaza,Prescription,PRIORITY; Orphan,36MG,To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),yes,yes,muscular,Duchenne muscular dystrophy,children and adults,2/9/2017
No,No,None,brodalumab,VALEANT LUXEMBOURG,INJECTABLE;INJECTION,,Siliq,Prescription,N/A,210MG/1.5ML,To treat adults with moderate-to-severe plaque psoriasis,yes,yes,muscular,Duchenne muscular dystrophy,children and adults,2/9/2017
Yes,Yes,None,telotristat ethyl,TERSERA,TABLET;ORAL,Type 1 - New Molecular Entity,Xermelo,Prescription,PRIORITY; Orphan,EQ 250MG BASE,To treat carcinoid syndrome diarrhea,no,no,immune disease,plaque psoriasis ,adults,2/15/2017
Yes,Yes,None,ribociclib,NOVARTIS,TABLET;ORAL,Type 1 - New Molecular Entity,Kisqali,Prescription,PRIORITY,EQ 200MG BASE,To treat postmenopausal women with a type of advanced breast cancer,yes,no,cancer,digestive,adults,2/28/2017
Yes,No,None,safinamide,MDD US,TABLET;ORAL,Type 1 - New Molecular Entity,Xadago,Prescription,STANDARD,50MG,To treat Parkinson’s disease,no,no,cancer,breast,female,3/13/2017
Yes,Yes,None,safinamide,MDD US,TABLET;ORAL,Type 1 - New Molecular Entity,Xadago,Prescription,STANDARD,100MG,To treat Parkinson’s disease,no,no,muscular,Parkinson’s disease,adults,3/21/2017
No,No,None,avelumab,EMD SERONO INC,INJECTABLE;INJECTION,,Bavencio,Prescription,N/A; Orphan,20MG/ML,To treat metastatic Merkel cell carcinoma,no,no,muscular,Parkinson’s disease,adults,3/21/2017
Yes,Yes,None,"
			",BDSI,TABLET;ORAL,Type 1 - New Molecular Entity,Symproic,Prescription,STANDARD,EQ 0.2MG BASE,"
			",yes,no,cancer,skin,children and adults,3/23/2017
Yes,Yes,None,niraparib,GLAXOSMITHKLINE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Zejula,Prescription,PRIORITY; Orphan,EQ 100MG BASE,"For the maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers",no,no,digestive,constipation,adults,3/23/2017
No,No,None,dupilumab,REGENERON PHARMACEUTICALS,INJECTABLE; INJECTION,,Dupixent,Prescription,N/A,150MG/ML,To treat adults with moderate-to-severe eczema (atopic dermatitis),no,no,cancer,ovary,female,3/27/2017
No,No,None,ocrelizumab,GENENTECH INC,INJECTABLE;INJECTION,,Ocrevus,Prescription,N/A,30MG/1ML,To treat patients with relapsing and primary progressive forms of multiple sclerosis,no,no,skin,skin,adults,3/28/2017
Yes,No,None,deutetrabenazine ,TEVA BRANDED PHARM,TABLET;ORAL,Type 1 - New Molecular Entity,Austedo,Prescription,STANDARD; Orphan,6MG,For the treatment of chorea associated with Huntington’s disease ,no,no,immune disease, multiple sclerosis,adults,3/28/2017
Yes,No,None,deutetrabenazine ,TEVA BRANDED PHARM,TABLET;ORAL,Type 1 - New Molecular Entity,Austedo,Prescription,STANDARD; Orphan,9MG,For the treatment of chorea associated with Huntington’s disease ,no,yes,neurology,Huntington’s disease.,adults,4/3/2017
Yes,Yes,None,deutetrabenazine ,TEVA BRANDED PHARM,TABLET;ORAL,Type 1 - New Molecular Entity,Austedo,Prescription,STANDARD; Orphan,12MG,For the treatment of chorea associated with Huntington’s disease ,no,yes,neurology,Huntington’s disease.,adults,4/3/2017
Yes,No,None,valbenazine,NEUROCRINE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ingrezza,Prescription,PRIORITY,EQ 40MG BASE,To treat adults with tardive dyskinesia ,no,yes,neurology,Huntington’s disease.,adults,4/3/2017
Yes,Yes,None,valbenazine,NEUROCRINE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ingrezza,Prescription,PRIORITY,EQ 80MG BASE,To treat adults with tardive dyskinesia ,no,no,muscular,Tardive dyskinesia ,adults,4/11/2017
No,No,None,cerliponase alfa,BIOMARIN PHARM,INJECTABLE;INJECTION,,Brineura,Prescription,N/A; Orphan,30MG/ML,To treat a specific form of Batten disease,no,no,muscular,Tardive dyskinesia ,adults,4/11/2017
Yes,No,None,brigatinib,ARIAD,TABLET;ORAL,Type 1 - New Molecular Entity,Alunbrig,Prescription,PRIORITY; Orphan,30MG,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,no,no,nervous system,Batten disease,children and adults,4/27/2017
Yes,No,None,brigatinib,ARIAD,TABLET;ORAL,Type 1 - New Molecular Entity,Alunbrig,Prescription,PRIORITY; Orphan,90MG,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,no,no,cancer,lung,adults,4/28/2017
Yes,Yes,None,brigatinib,ARIAD,TABLET;ORAL,Type 1 - New Molecular Entity,Alunbrig,Prescription,PRIORITY; Orphan,180MG,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,no,no,cancer,lung,adults,4/28/2017
Yes,Yes,None,midostaurin,NOVARTIS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Rydapt,Prescription,PRIORITY; Orphan,25MG,"To treat acute myeloid leukemia, advanced systemic mastocytosis",no,no,cancer,lung,adults,4/28/2017
Yes,Yes,None,abaloparatide,RADIUS HEALTH INC,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Tymlos,Prescription,STANDARD,3.12MG/1.56ML (2MG/ML),To treat osteoporosis in postmenopausal women at high risk of fracture or those who have failed other therapies,no,no,cancer,blood,adults,4/28/2017
TBD,No,None,durvalumab,ASTRAZENECA UK LTD,INJECTABLE;INJECTION,,Imfinzi,Prescription,N/A,50MG/ML,To treat patients with locally advanced or metastatic urothelial carcinoma,no,no,immune disease,osteoporosis,female,4/28/2017
Yes,Yes,None,edaravone,MITSUBISHI TANABE,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Radicava,Prescription,STANDARD; Orphan,30MG/100ML (0.3MG/ML),To treat patients with amyotrophic lateral sclerosis (ALS),no,no,cancer,nephrology,adults,5/1/2017
Yes,Yes,None,edaravone,MITSUBISHI TANABE,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Radicava,Prescription,STANDARD; Orphan,60MG/100ML (0.6MG/ML),To treat patients with amyotrophic lateral sclerosis (ALS),yes,no,nervous system,amyotrophic lateral sclerosis,adults,5/5/2017
TBD,No,None,sarilumab,SANOFI SYNTHELABO,INJECTABLE;INJECTION,,Kevzara,Prescription,N/A,150MG/1.14ML,,yes,no,nervous system,amyotrophic lateral sclerosis,adults,5/5/2017
TBD,No,None,sarilumab,SANOFI SYNTHELABO,INJECTABLE;INJECTION,,Kevzara,Prescription,N/A,200MG/1.14ML,,no,no,immune disease,rheumatoid arthritis,adults,5/22/2017
Yes,Yes,None,delafloxacin,MELINTA,TABLET;ORAL,Type 1 - New Molecular Entity,Baxdela,Prescription,PRIORITY,EQ 450MG BASE,To treat patients with acute bacterial skin infections,no,no,immune disease,rheumatoid arthritis,adults,5/22/2017
Yes,No,None,betrixaban,PORTOLA PHARMS INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Bevyxxa,Discontinued,PRIORITY,40MG,For the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness,no,no,vector-borne diseases,infection,adults,6/19/2017
Yes,No,None,betrixaban,PORTOLA PHARMS INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Bevyxxa,Discontinued,PRIORITY,80MG,For the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness,no,no,cardiovascular,blood,adults,6/23/2017
No,No,None,guselkumab,JANSSEN BIOTECH,INJECTABLE;INJECTION,,Tremfya,Prescription,N/A,100MG/ML,For the treatment of adult patients with moderate-to-severe plaque psoriasis,no,no,cardiovascular,blood,adults,6/23/2017
Yes,Yes,None,neratinib maleate,PUMA BIOTECH,TABLET;ORAL,Type 1 - New Molecular Entity,Nerlynx,Prescription,STANDARD,EQ 40MG BASE,To reduce the risk of breast cancer returning,no,no,immune disease,plaque psoriasis ,adults,7/13/2017
Yes,Yes,None,"sofosbuvir, velpatasvir and voxilaprevir",GILEAD SCIENCES INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Vosevi,Prescription,PRIORITY,400MG;100MG;100MG,To treat adults with chronic hepatitis C virus,no,no,cancer,breast,female,7/17/2017
Yes,No,None,enasidenib,CELGENE CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Idhifa,Prescription,PRIORITY; Orphan,EQ 50MG BASE,To treat relapsed or refractory acute myeloid leukemia,no,no,hepatitis C,liver,adults,7/18/2017
Yes,Yes,None,enasidenib,CELGENE CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Idhifa,Prescription,PRIORITY; Orphan,EQ 100MG BASE,To treat relapsed or refractory acute myeloid leukemia,no,no,cancer,blood,adults,8/1/2017
Yes,Yes,None,glecaprevir and pibrentasvir,ABBVIE INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Mavyret,Prescription,PRIORITY; Orphan,100MG;40MG,To treat adults with chronic hepatitis C virus,no,no,cancer,blood,adults,8/1/2017
TBD,No,None,inotuzumab ozogamicin,WYETH PHARMS INC,"POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER",,Besponsa,Prescription,N/A; Orphan,0.9/MG/VIAL,To treat adults with relapsed or refractory acute lymphoblastic leukemia,no,no,hepatitis C,liver,adults,8/3/2017
Yes,Yes,None,meropenem and vaborbactam,REMPEX,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Vabomere,Prescription,PRIORITY,1GM/VIAL;1GM/VIAL,To treat adults with complicated urinary tract infections,no,no,cancer,blood,adults,8/17/2017
Yes,No,None,benznidazole,CHEMO RESEARCH SL,TABLET;ORAL,Type 1 - New Molecular Entity,benznidazole,Prescription,PRIORITY; Orphan,12.5MG,To treat children ages 2 to 12 years old with Chagas disease,no,no,nephrology,UTI,adults,8/29/2017
Yes,Yes,None,benznidazole,CHEMO RESEARCH SL,TABLET;ORAL,Type 1 - New Molecular Entity,benznidazole,Prescription,PRIORITY; Orphan,100MG,To treat children ages 2 to 12 years old with Chagas disease,no,no,insect bite,Chagas disease,children,8/29/2017
Yes,Yes,None,copanlisib,BAYER HEALTHCARE,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Aliqopa,Prescription,PRIORITY; Orphan,60MG/VIAL,To treat adults with relapsed follicular lymphoma,no,no,insect bite,Chagas disease,children,8/29/2017
Yes,Yes,None,secnidazole,LUPIN,GRANULE;ORAL,Type 1 - New Molecular Entity,Solosec,Prescription,PRIORITY,2GM/PACKET,To treat bacterial vaginosis,no,no,cancer,lymph node,adults,9/14/2017
Yes,No,None,abemaciclib,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Verzenio,Prescription,PRIORITY,50MG,To treat certain advanced or metastatic breast cancers,no,no,vector-borne diseases,infection,female,9/15/2017
Yes,No,None,abemaciclib,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Verzenio,Prescription,PRIORITY,100MG,To treat certain advanced or metastatic breast cancers,no,no,cancer,breast,female,9/28/2017
Yes,No,None,abemaciclib,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Verzenio,Prescription,PRIORITY,150MG,To treat certain advanced or metastatic breast cancers,no,no,cancer,breast,female,9/28/2017
Yes,Yes,None,abemaciclib,ELI LILLY AND CO,TABLET;ORAL,Type 1 - New Molecular Entity,Verzenio,Prescription,PRIORITY,200MG,To treat certain advanced or metastatic breast cancers,no,no,cancer,breast,female,9/28/2017
Yes,Yes,None,acalabrutinib,ASTRAZENECA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Calquence,Prescription,PRIORITY; Orphan,100MG,To treat adults with mantle cell lymphoma,no,no,cancer,breast,female,9/28/2017
Yes,Yes,None,latanoprostene bunod ophthalmic solution,BAUSCH AND LOMB,SOLUTION/DROPS;OPHTHALMIC,Type 1 - New Molecular Entity,Vyzulta,Prescription,STANDARD,0.024%,To treat intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,no,no,cancer,lymph node,male,10/31/2017
Yes,No,None,letermovir,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Prevymis,Prescription,PRIORITY; Orphan,240MG,To prevent infection after bone marrow transplant,no,no,muscular,eye,male,11/2/2017
Yes,Yes,None,letermovir,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Prevymis,Prescription,PRIORITY; Orphan,480MG,To prevent infection after bone marrow transplant,no,no,vector-borne diseases,infection,male,11/8/2017
TBD,No,None,benralizumab ,ASTRAZENECA AB,INJECTABLE;INJECTION,,Fasenra ,Prescription,N/A,30MG/ML,"For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype",no,no,vector-borne diseases,infection,male,11/8/2017
No,No,None,,ULTRAGENYX PHARM INC,INJECTABLE;INJECTION,,Mepsevii,Prescription,N/A; Orphan,10MG/5ML,"To treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.",no,no,pulmonary,asthma,children and adults,11/14/2017
TBD,No,None,,GENENTECH INC,INJECTABLE;INJECTION,,Hemlibra,Prescription,N/A; Orphan,30MG/ML,To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.,yes,yes,immune disease,enzyme,adults,11/15/2017
TBD,No,None,,GENENTECH INC,INJECTABLE;INJECTION,,Hemlibra,Prescription,N/A; Orphan,60MG/0.4ML,To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.,no,no,cardiovascular,anemia,children and adults,11/16/2017
TBD,No,None,,GENENTECH INC,INJECTABLE;INJECTION,,Hemlibra,Prescription,N/A; Orphan,105MG/0.7ML,To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.,no,no,cardiovascular,anemia,children and adults,11/16/2017
TBD,No,None,,GENENTECH INC,INJECTABLE;INJECTION,,Hemlibra,Prescription,N/A; Orphan,150MG,To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.,no,no,cardiovascular,anemia,children and adults,11/16/2017
Yes,Yes,None,semaglutide,NOVO,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Ozempic,Prescription,STANDARD,2MG/1.5ML (1.34MG/ML),To improve glycemic control in adults with type 2 diabetes mellitus,no,no,cardiovascular,anemia,children and adults,11/16/2017
Yes,Yes,None,semaglutide,NOVO,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Ozempic,Prescription,STANDARD,4MG/3ML (1.34MG/ML),To improve glycemic control in adults with type 2 diabetes mellitus,no,no,endocrinology,type 2 diabetes,adults,12/5/2017
Yes,Yes,None,ozenoxacin,FERRER INTERNACIONAL,CREAM;TOPICAL,Type 1 - New Molecular Entity,Xepi,Prescription,STANDARD,1%,To treat impetigo,no,no,endocrinology,type 2 diabetes,adults,12/5/2017
Yes,Yes,None,netarsudil,AERIE PHARMS INC,SOLUTION/DROPS;OPHTHALMIC,Type 1 - New Molecular Entity,Rhopressa,Prescription,STANDARD,EQ 0.02% BASE,To treat glaucoma or ocular hypertension,no,no,vector-borne diseases,infection,"infant, children and adult",12/11/2017
Yes,No,None,ertugliflozin,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Steglatro,Prescription,STANDARD,5MG,,no,no,muscular,eye,adults,12/18/2017
Yes,Yes,None,ertugliflozin,MERCK SHARP DOHME,TABLET;ORAL,Type 1 - New Molecular Entity,Steglatro,Prescription,STANDARD,15MG,,no,no,endocrinology,type 2 diabetes,adults,12/19/2017
Yes,Yes,None,macimorelin acetate,NOVO,FOR SOLUTION;ORAL,Type 1 - New Molecular Entity,Macrilen,Prescription,STANDARD; Orphan,EQ 60MG BASE/POUCH,,no,no,endocrinology,type 2 diabetes,adults,12/19/2017
Yes,Yes,None,angiotensin II,LA JOLLA PHARMA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Giapreza,Prescription,PRIORITY,EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML),To increase blood pressure in adults with septic or other distributive shock,no,no,endocrinology,endocrinology,adults,12/20/2017
Yes,No,None,angiotensin II,LA JOLLA PHARMA,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Giapreza,Discontinued,PRIORITY,EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML),To increase blood pressure in adults with septic or other distributive shock,no,no,cardiovascular,blood,adults,12/21/2017
Yes,No,None,brivaracetam,UCB INC,TABLET;ORAL,Type 1 - New Molecular Entity,Briviact,Prescription,STANDARD,10MG,To treat partial onset seizures in patients age 16 years and older with epilepsy.,no,no,cardiovascular,blood,adults,12/21/2017
Yes,No,None,brivaracetam,UCB INC,TABLET;ORAL,Type 1 - New Molecular Entity,Briviact,Prescription,STANDARD,25MG,To treat partial onset seizures in patients age 16 years and older with epilepsy.,no,no,nervous system,seizures,children and adults,2/18/2016
Yes,No,None,brivaracetam,UCB INC,TABLET;ORAL,Type 1 - New Molecular Entity,Briviact,Prescription,STANDARD,50MG,To treat partial onset seizures in patients age 16 years and older with epilepsy.,no,no,nervous system,seizures,children and adults,2/18/2016
Yes,No,None,brivaracetam,UCB INC,TABLET;ORAL,Type 1 - New Molecular Entity,Briviact,Prescription,STANDARD,75MG,To treat partial onset seizures in patients age 16 years and older with epilepsy.,no,no,nervous system,seizures,children and adults,2/18/2016
Yes,Yes,None,brivaracetam,UCB INC,TABLET;ORAL,Type 1 - New Molecular Entity,Briviact,Prescription,STANDARD,100MG,To treat partial onset seizures in patients age 16 years and older with epilepsy.,no,no,nervous system,seizures,children and adults,2/18/2016
No,No,None,obiltoxaximab,ELUSYS THERAPEUTICS INC,INJECTABLE;INJECTION,,Anthim,Prescription,N/A; Orphan,600MG/6ML,To treat inhalational anthrax in combination with appropriate antibacterial drugs.,no,no,nervous system,seizures,children and adults,2/18/2016
No,No,None,ixekizumab,ELI LILLY AND CO,INJECTABLE;INJECTION,,Taltz,Prescription,N/A,80MG/ML,To treat adults with moderate-to-severe plaque psoriasis. ,no,no,vector-borne diseases,infection,adults,3/18/2016
No,No,None,reslizumab,TEVA RESPIRATORY LLC,INJECTABLE;INJECTION,,Cinqair,Prescription,N/A,100MG/10ML,To treat severe asthma,no,no,immune disease,plaque psoriasis,adults,3/22/2016
Yes,Yes,None,defibrotide sodium,JAZZ PHARMS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Defitelio,Prescription,PRIORITY; Orphan,200MG/2.5ML (80MG/ML),To treat adults and children who develop ,no,no,pulmonary,asthma,adults,3/23/2016
Yes,No,None,venetoclax,ABBVIE INC,TABLET;ORAL,Type 1 - New Molecular Entity,Venclexta,Prescription,PRIORITY; Orphan,10MG,For chronic lymphocytic leukemia in patients with a specific chromosomal abnormality,no,no,hepatic,hepatic,adults,3/30/2016
Yes,No,None,venetoclax,ABBVIE INC,TABLET;ORAL,Type 1 - New Molecular Entity,Venclexta,Prescription,PRIORITY; Orphan,50MG,For chronic lymphocytic leukemia in patients with a specific chromosomal abnormality,no,no,cancer,blood,adults,4/11/2016
Yes,Yes,None,venetoclax,ABBVIE INC,TABLET;ORAL,Type 1 - New Molecular Entity,Venclexta,Prescription,PRIORITY; Orphan,100MG,For chronic lymphocytic leukemia in patients with a specific chromosomal abnormality,no,no,cancer,blood,adults,4/11/2016
Yes,No,None,pimavanserin,ACADIA PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Nuplazid,Discontinued,PRIORITY,EQ 17MG BASE,To treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease,no,no,cancer,blood,adults,4/11/2016
Yes,Yes,None,pimavanserin,ACADIA PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Nuplazid,Prescription,PRIORITY,EQ 10MG BASE,To treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease,no,no,muscular,Parkinson’s disease,adults,4/29/2016
No,No,None,atezolizumab,GENENTECH INC,INJECTABLE;INJECTION,,Tecentriq,Prescription,N/A,1200MG/20ML,"To treat urothelial carcinoma, the most common type of bladder cancer",no,no,muscular,Parkinson’s disease,adults,4/29/2016
TBD,No,None,daclizumab,BIOGEN,INJECTABLE;INJECTION,,Zinbryta,Prescription,N/A,150MG/ML,To treat multiple sclerosis,no,no,cancer,nephrology,adults,5/18/2016
Yes,No,None,obeticholic acid,INTERCEPT PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Ocaliva,Prescription,PRIORITY; Orphan,5MG,"To treat rare, chronic liver disease",yes,no,immune disease,multiple sclerosis,adults,5/27/2016
Yes,Yes,None,obeticholic acid,INTERCEPT PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Ocaliva,Prescription,PRIORITY; Orphan,10MG,"To treat rare, chronic liver disease",no,no,hepatic,liver,adults,5/27/2016
Yes,Yes,None,fluciclovine F 18,BLUE EARTH,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Axumin,Prescription,PRIORITY,9-221mCi/ML,A  new diagnostic imaging agent to detect recurrent prostate cancer,no,no,hepatic,liver,adults,5/27/2016
Yes,Yes,None,gallium Ga 68 dotatate,AAA USA INC,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,NETSPOT,Prescription,PRIORITY; Orphan,2.1-5.5mCi/ML,A diagnostic imaging agent to detect rare neuroendocrine tumors,no,no,cancer,imaging,adults,5/27/2016
Yes,Yes,None,sofosbuvir and velpatasvir,GILEAD SCIENCES INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Epclusa,Prescription,PRIORITY,400MG;100MG,To treat all six major forms of hepatitis C virus,no,no,cancer,imaging,adults,6/1/2016
Yes,No,None,sofosbuvir and velpatasvir,GILEAD SCIENCES INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Epclusa,Prescription,PRIORITY,200MG;50MG,To treat all six major forms of hepatitis C virus,no,no,hepatitis C,liver,adults,6/28/2016
Yes,Yes,None,lifitegrast ophthalmic solution,NOVARTIS,SOLUTION/DROPS;OPHTHALMIC,Type 1 - New Molecular Entity,Xiidra,Prescription,PRIORITY,5%,To treat the signs and symptoms of dry eye disease,no,no,hepatitis C,liver,adults,6/28/2016
No,No,None,lixisenatide,SANOFI-AVENTIS US,SOLUTION;SUBCUTANEOUS,,Adlyxin,Prescription,N/A,0.15MG/3ML (0.05MG/ML),To improve glycemic control (blood sugar levels),no,no,muscular,eye,adults,7/11/2016
No,No,None,lixisenatide,SANOFI-AVENTIS US,SOLUTION;SUBCUTANEOUS,,Adlyxin,Prescription,N/A,0.3MG/3ML (0.1MG/ML),To improve glycemic control (blood sugar levels),no,no,endocrinology,type 2 diabetes,adults,7/27/2016
Yes,Yes,None,eteplirsen,SAREPTA THERAPS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Exondys 51,Prescription,PRIORITY; Orphan,100MG/2ML (50MG/ML),To treat patients with Duchenne muscular dystrophy,no,no,endocrinology,type 2 diabetes,adults,7/27/2016
Yes,Yes,None,eteplirsen,SAREPTA THERAPS INC,SOLUTION;INTRAVENOUS,Type 1 - New Molecular Entity,Exondys 51,Prescription,PRIORITY; Orphan,500MG/10ML (50MG/ML),To treat patients with Duchenne muscular dystrophy,no,no,muscular,Duchenne muscular dystrophy,male,9/19/2016
No,No,None,olaratumab,ELI LILLY AND CO,INJECTABLE; INJECTION,,Lartruvo,Prescription,N/A; Orphan,500MG/50ML,To treat adults with certain types of soft tissue sarcoma,no,no,muscular,Duchenne muscular dystrophy,male,9/19/2016
No,No,None,bezlotoxumab,MERCK SHARP DOHME,INJECTABLE;INJECTION,,Zinplava,Prescription,N/A,1000ML/40ML,To reduce the recurrence of Clostridium difficile infection in patients aged 18 years or older,no,no,cancer,skin,adults,10/19/2016
Yes,Yes,None,crisaborole,ANACOR PHARMS INC,OINTMENT;TOPICAL,Type 1 - New Molecular Entity,Eucrisa,Prescription,STANDARD,2%,To treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older,no,no,vector-borne diseases,infection,adults,10/21/2016
Yes,No,None,rucaparib,CLOVIS ONCOLOGY INC,TABLET;ORAL,Type 1 - New Molecular Entity,Rubraca,Prescription,PRIORITY; Orphan,EQ 200MG BASE,"
			",no,no,skin,infection,children and adults,12/14/2016
Yes,Yes,None,rucaparib,CLOVIS ONCOLOGY INC,TABLET;ORAL,Type 1 - New Molecular Entity,Rubraca,Prescription,PRIORITY; Orphan,EQ 300MG BASE,"
			",no,no,cancer,ovary,female,12/19/2016
Yes,No,None,rucaparib,CLOVIS ONCOLOGY INC,TABLET;ORAL,Type 1 - New Molecular Entity,Rubraca,Prescription,PRIORITY; Orphan,EQ 250MG BASE,"
			",no,no,cancer,ovary,female,12/19/2016
Yes,Yes,None,nusinersen,BIOGEN IDEC,SOLUTION;INTRATHECAL,Type 1 - New Molecular Entity,Spinraza,Prescription,PRIORITY; Orphan,EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML),To treat children and adults with spinal muscular atrophy (SMA),no,no,neurology,neurology,adults,12/19/2016
TBD,No,,secukinumab,NOVARTIS PHARMS CORP,INJECTABLE;INJECTION,,Cosentyx,Prescription,N/A,150MG/ML,To treat adults with moderate-to-severe plaque psoriasis,no,yes,immune disease,plaque psoriasis,children and adults,12/23/2016
TBD,No,,parathyroid horomone,NPS PHARMS INC,INJECTABLE;INJECTION,,Natpara,Prescription,N/A; Orphan,25MCG,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism,no,no,endocrinology,calcium,adults,1/21/2015
TBD,No,,parathyroid horomone,NPS PHARMS INC,INJECTABLE;INJECTION,,Natpara,Prescription,N/A; Orphan,50MCG,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism,no,no,endocrinology,calcium,adults,1/23/2015
TBD,No,,parathyroid horomone,NPS PHARMS INC,INJECTABLE;INJECTION,,Natpara,Prescription,N/A; Orphan,75MCG,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism,no,no,endocrinology,calcium,adults,1/23/2015
TBD,No,,parathyroid horomone,NPS PHARMS INC,INJECTABLE;INJECTION,,Natpara,Prescription,N/A; Orphan,100MCG,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism,no,no,endocrinology,calcium,adults,1/23/2015
Yes,No,None,palbociclib,PFIZER,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ibrance,Prescription,PRIORITY,75MG,To treat advanced (metastatic) breast cancer,no,no,cancer,breast,female,1/23/2015
Yes,No,None,palbociclib,PFIZER,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ibrance,Prescription,PRIORITY,100MG,To treat advanced (metastatic) breast cancer,no,no,cancer,breast,female,2/3/2015
Yes,Yes,None,palbociclib,PFIZER,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ibrance,Prescription,PRIORITY,125MG,To treat advanced (metastatic) breast cancer,no,no,cancer,breast,female,2/3/2015
Yes,No,None,lenvatinib,EISAI INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Lenvima,Prescription,PRIORITY; Orphan,EQ 4MG BASE,"To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).",no,no,cancer,thyroid,adults,2/3/2015
Yes,Yes,None,lenvatinib,EISAI INC,CAPSULE;ORAL,Type 1 - New Molecular Entity,Lenvima,Prescription,PRIORITY; Orphan,EQ 10MG BASE,"To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).",no,no,cancer,thyroid,adults,2/13/2015
Yes,No,None,panobinostat,SECURA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Farydak,Prescription,PRIORITY; Orphan,EQ 10MG BASE,To treat patients with multiple myeloma,no,no,cancer,blood,adults,2/13/2015
Yes,No,None,panobinostat,SECURA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Farydak,Prescription,PRIORITY; Orphan,EQ 15MG BASE,To treat patients with multiple myeloma,no,no,cancer,blood,adults,2/23/2015
Yes,Yes,None,panobinostat,SECURA,CAPSULE;ORAL,Type 1 - New Molecular Entity,Farydak,Prescription,PRIORITY; Orphan,EQ 20MG BASE,To treat patients with multiple myeloma,no,no,cancer,blood,adults,2/23/2015
Yes,Yes,None,ceftazidime-avibactam,ALLERGAN,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity and Type 4 - New Combination,Avycaz,Prescription,PRIORITY,EQ 0.5GM BASE;2GM/VIAL,"To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.",no,no,nephrology,UTI,adults,2/23/2015
Yes,Yes,None,isavuconazonium sulfate,ASTELLAS,POWDER;INTRAVENOUS,Type 3 - New Dosage Form,capsule,Prescription,PRIORITY; Orphan,372MG,"To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections",no,no,vector-borne diseases,infection,adults,2/25/2015
Yes,Yes,None,isavuconazonium sulfate,ASTELLAS,CAPSULE;ORAL,Type 1 - New Molecular Entity,capsule,Prescription,PRIORITY; Orphan,186MG,"To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections",yes,no,vector-borne diseases,infection,adults,3/6/2015
No,No,None,dinutuximab,UNITED THERAP,INJECTABLE;INTRAVENOUS,,Unituxin,Prescription,N/A; Orphan,17.5MG/5ML,To treat pediatric patients with high-risk neuroblastoma,yes,no,cancer,nervous system,children,3/6/2015
Yes,No,None,cholic acid,TRAVERE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Cholbam,Prescription,PRIORITY; Orphan,50MG,"To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders",no,no,digestive,digestive,adults,3/10/2015
Yes,Yes,None,cholic acid,TRAVERE,CAPSULE;ORAL,Type 1 - New Molecular Entity,Cholbam,Prescription,PRIORITY; Orphan,250MG,"To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders",no,no,digestive,digestive,adults,3/17/2015
Yes,No,None,ivabradine,AMGEN INC,TABLET;ORAL,Type 1 - New Molecular Entity,Corlanor,Prescription,PRIORITY,EQ 5MG BASE,To reduce hospitalization from worsening heart failure.,no,no,cardiovascular,cardiovascular,adults,3/17/2015
Yes,Yes,None,ivabradine,AMGEN INC,TABLET;ORAL,Type 1 - New Molecular Entity,Corlanor,Prescription,PRIORITY,EQ 7.5MG BASE,To reduce hospitalization from worsening heart failure.,no,no,cardiovascular,cardiovascular,adults,4/15/2015
Yes,Yes,None,deoxycholic acid,KYTHERA BIOPHARMS,SOLUTION;SUBCUTANEOUS,Type 1 - New Molecular Entity,Kybella,Prescription,STANDARD,20MG/2ML (10MG/ML),"To treat adults with moderate-to-severe fat below the chin, known as submental fat",no,no,cosmetic,chin-fat,adults,4/15/2015
Yes,No,None,eluxadoline,ALLERGAN HOLDINGS,TABLET;ORAL,Type 1 - New Molecular Entity,Viberzi,Prescription,PRIORITY,75MG,To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.,no,no,digestive,diarrhea,adults,4/29/2015
Yes,Yes,None,eluxadoline,ALLERGAN HOLDINGS,TABLET;ORAL,Type 1 - New Molecular Entity,Viberzi,Prescription,PRIORITY,100MG,To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.,no,no,digestive,diarrhea,adults,5/27/2015
Yes,Yes,None,"
			",CHIESI,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Kengreal,Prescription,STANDARD,50MG/VIAL,To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary intervention,no,no,cardiovascular,blood,adults,5/27/2015
Yes,Yes,None,lumacaftor 200 mg/ivacaftor 125 mg,VERTEX PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Orkambi,Prescription,PRIORITY; Orphan,125MG;200MG,To treat cystic fibrosis,no,no,immune disease,cystic fibrosis,adults,6/22/2015
Yes,No,None,lumacaftor 200 mg/ivacaftor 125 mg,VERTEX PHARMS INC,TABLET;ORAL,Type 1 - New Molecular Entity,Orkambi,Prescription,PRIORITY; Orphan,125MG;100MG,To treat cystic fibrosis,no,no,immune disease,cystic fibrosis,adults,7/2/2015
Yes,No,None,sacubitril/valsartan,NOVARTIS PHARMS CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Entresto,Prescription,PRIORITY,24MG;26MG,To treat heart failure,no,no,cardiovascular,heart,adults,7/2/2015
Yes,No,None,sacubitril/valsartan,NOVARTIS PHARMS CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Entresto,Prescription,PRIORITY,49MG;51MG,To treat heart failure,no,no,cardiovascular,heart,adults,7/7/2015
Yes,Yes,None,sacubitril/valsartan,NOVARTIS PHARMS CORP,TABLET;ORAL,Type 1 - New Molecular Entity,Entresto,Prescription,PRIORITY,97MG;103MG,To treat heart failure,no,no,cardiovascular,heart,adults,7/7/2015
Yes,No,None,brexpiprazole,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Rexulti,Prescription,STANDARD,0.25MG,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,no,no,mental health,mental health,adults,7/7/2015
Yes,No,None,brexpiprazole,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Rexulti,Prescription,STANDARD,0.5MG,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,no,no,mental health,mental health,adults,7/10/2015
Yes,No,None,brexpiprazole,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Rexulti,Prescription,STANDARD,1MG,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,no,no,mental health,mental health,adults,7/10/2015
Yes,Yes,None,brexpiprazole,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Rexulti,Prescription,STANDARD,2MG,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,no,no,mental health,mental health,adults,7/10/2015
Yes,No,None,brexpiprazole,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Rexulti,Prescription,STANDARD,3MG,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,no,no,mental health,mental health,adults,7/10/2015
Yes,No,None,brexpiprazole,OTSUKA,TABLET;ORAL,Type 1 - New Molecular Entity,Rexulti,Prescription,STANDARD,4MG,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,no,no,mental health,mental health,adults,7/10/2015
TBD,No,None,alirocumab,SANOFI AVENTIS,INJECTABLE;INJECTION,,Praluent,Prescription,N/A,75MG,"
			",no,no,cardiovascular,cholesterol,adults,7/10/2015
TBD,No,None,alirocumab,SANOFI AVENTIS,INJECTABLE;INJECTION,,Praluent,Prescription,N/A,150MG,"
			",no,no,cardiovascular,cholesterol,adults,7/24/2015
Yes,Yes,None,sonidegib,SUN PHARMA GLOBAL,CAPSULE;ORAL,Type 1 - New Molecular Entity,Odomzo,Prescription,STANDARD,EQ 200MG BASE,"To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.",no,no,cardiovascular,cholesterol,adults,7/24/2015
Yes,Yes,None,rolapitant,TERSERA,TABLET;ORAL,Type 1 - New Molecular Entity,Varubi,Prescription,STANDARD,EQ 90MG BASE,To prevent delayed phase chemotherapy-induced nausea and vomiting (emesis),no,no,cancer,nausea,adults,7/24/2015
Yes,Yes,None,uridine triacetate,WELLSTAT THERAP,GRANULE;ORAL,Type 1 - New Molecular Entity,Xuriden,Prescription,PRIORITY; Orphan,2GM/PACKET,To treat patients with hereditary orotic aciduria,no,no,nephrology,nephrology,adults,9/1/2015
Yes,No,None,cariprazine,ALLERGAN,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vraylar,Prescription,STANDARD,EQ 1.5MG BASE,To treat schizophrenia and bipolar disorder in adults,yes,yes,mental health,schizophrenia,adults,9/4/2015
Yes,No,None,cariprazine,ALLERGAN,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vraylar,Prescription,STANDARD,EQ 3MG BASE,To treat schizophrenia and bipolar disorder in adults,no,no,mental health,schizophrenia,adults,9/17/2015
Yes,No,None,cariprazine,ALLERGAN,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vraylar,Prescription,STANDARD,EQ 4.5MG BASE,To treat schizophrenia and bipolar disorder in adults,no,no,mental health,schizophrenia,adults,9/17/2015
Yes,Yes,None,cariprazine,ALLERGAN,CAPSULE;ORAL,Type 1 - New Molecular Entity,Vraylar,Prescription,STANDARD,EQ 6MG BASE,To treat schizophrenia and bipolar disorder in adults,no,no,mental health,schizophrenia,adults,9/17/2015
Yes,No,None,trifluridine and tipiracil,TAIHO ONCOLOGY,TABLET;ORAL,Type 1 - New Molecular Entity,Lonsurf,Prescription,STANDARD,EQ 6.14MG BASE;15MG,To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapies,no,no,cancer,colorectal,adults,9/17/2015
Yes,Yes,None,trifluridine and tipiracil,TAIHO ONCOLOGY,TABLET;ORAL,Type 1 - New Molecular Entity,Lonsurf,Prescription,STANDARD,EQ 8.19MG BASE;20MG,To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapies,no,no,cancer,colorectal,adults,9/22/2015
No,No,None,insulin degludec injection,NOVO,SOLUTION;SUBCUTANEOUS,,Tresiba,Prescription,N/A,300 UNITS/3ML (100 UNITS/ML),To improve blood sugar (glucose) control in adults with diabetes mellitus,no,no,endocrinology,type 2 diabetes,adults,9/22/2015
No,No,None,insulin degludec injection,NOVO,SOLUTION;SUBCUTANEOUS,,Tresiba,Prescription,N/A,600 UNITS/3ML (200 UNITS/ML),To improve blood sugar (glucose) control in adults with diabetes mellitus,no,no,endocrinology,type 2 diabetes,adults,9/25/2015
No,No,None,insulin degludec injection,NOVO,SOLUTION;SUBCUTANEOUS,,Tresiba,Prescription,N/A,1000 UNITS/10ML (100 UNITS/ML),To improve blood sugar (glucose) control in adults with diabetes mellitus,no,no,endocrinology,type 2 diabetes,adults,9/25/2015
Yes,No,None,aripiprazole lauroxil,ALKERMES INC,"SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR",Type 1 - New Molecular Entity,Aristada,Prescription,STANDARD,441MG/1.6ML (275.63MG/ML),To treat adults with schizophrenia,no,no,mental health,schizophrenia,adults,9/25/2015
Yes,No,None,aripiprazole lauroxil,ALKERMES INC,"SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR",Type 1 - New Molecular Entity,Aristada,Prescription,STANDARD,662MG/2.4ML (275.83MG/ML),To treat adults with schizophrenia,no,no,mental health,schizophrenia,adults,10/5/2015
Yes,Yes,None,aripiprazole lauroxil,ALKERMES INC,"SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR",Type 1 - New Molecular Entity,Aristada,Prescription,STANDARD,882MG/3.2ML (275.63MG/ML),To treat adults with schizophrenia,no,no,mental health,schizophrenia,adults,10/5/2015
Yes,No,None,aripiprazole lauroxil,ALKERMES INC,"SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR",Type 1 - New Molecular Entity,Aristada,Prescription,STANDARD,1064MG/3.9ML (272.82MG/ML),To treat adults with schizophrenia,no,no,mental health,schizophrenia,adults,10/5/2015
No,No,None,idarucizumab,BOEHRINGER INGELHEIM,INJECTABLE;INJECTION,,Praxbind,Prescription,N/A,2.5G/50ML,For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.,no,no,cardiovascular,cardiovascular,adults,10/5/2015
Yes,No,None,patiromer for oral suspension,RELYPSA INC,POWDER;ORAL,Type 1 - New Molecular Entity,Veltassa,Prescription,STANDARD,EQ 8.4GM BASE/PACKET,"To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.",yes,no,cardiovascular,anemia,adults,10/16/2015
Yes,No,None,patiromer for oral suspension,RELYPSA INC,POWDER;ORAL,Type 1 - New Molecular Entity,Veltassa,Prescription,STANDARD,EQ 16.8GM BASE/PACKET,"To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.",no,no,cardiovascular,anemia,adults,10/21/2015
Yes,Yes,None,patiromer for oral suspension,RELYPSA INC,POWDER;ORAL,Type 1 - New Molecular Entity,Veltassa,Prescription,STANDARD,EQ 25.2GM BASE/PACKET,"To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.",no,no,cardiovascular,anemia,adults,10/21/2015
Yes,Yes,None,trabectedin,JANSSEN PRODS,POWDER;INTRAVENOUS,Type 1 - New Molecular Entity,Yondelis,Prescription,PRIORITY; Orphan,1MG/VIAL,To treat specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery ,no,no,cancer,muscle,adults,10/21/2015
No,No,None,asfotase alfa,ALEXION PHARM,SOLUTION;INJECTION,,Strensiq,Prescription,N/A; Orphan,18MG/0.45ML,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).",no,no,metabolic,metabolic,adults,10/23/2015
No,No,None,asfotase alfa,ALEXION PHARM,SOLUTION;INJECTION,,Strensiq,Prescription,N/A; Orphan,28MG/0.7ML,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).",yes,yes,metabolic,metabolic,"infant, children and adult",10/23/2015
No,No,None,asfotase alfa,ALEXION PHARM,SOLUTION;INJECTION,,Strensiq,Prescription,N/A; Orphan,40MG/ML,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).",yes,yes,metabolic,metabolic,"infant, children and adult",10/23/2015
No,No,None,asfotase alfa,ALEXION PHARM,SOLUTION;INJECTION,,Strensiq,Prescription,N/A; Orphan,80MG/0.8ML,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).",yes,yes,metabolic,metabolic,"infant, children and adult",10/23/2015
No,No,None,mepolizumab,GLAXOSMITHKLINE LLC,INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER,,Nucala,Prescription,N/A,100MG,,yes,yes,metabolic,metabolic,"infant, children and adult",10/23/2015
Yes,Yes,None,"a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide",GILEAD SCIENCES INC,TABLET;ORAL,Type 1 - New Molecular Entity and Type 4 - New Combination,Genvoya,Prescription,STANDARD,150MG;150MG;200MG;EQ 10MG BASE,For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older,yes,yes,HIV,liver,"infant, children and adult",11/4/2015
Yes,Yes,None,cobimetinib,GENENTECH INC,TABLET;ORAL,Type 1 - New Molecular Entity,Cotellic,Prescription,PRIORITY; Orphan,EQ 20MG BASE,"To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)",yes,yes,cancer,skin,children and adults,11/5/2015
Yes,No,None,osimertinib,ASTRAZENECA,TABLET;ORAL,Type 1 - New Molecular Entity,Tagrisso,Prescription,PRIORITY; Orphan,EQ 40MG BASE,To treat certain patients with non-small cell lung cancer,no,no,cancer,lung,adults,11/10/2015
Yes,Yes,None,osimertinib,ASTRAZENECA,TABLET;ORAL,Type 1 - New Molecular Entity,Tagrisso,Prescription,PRIORITY; Orphan,EQ 80MG BASE,To treat certain patients with non-small cell lung cancer,no,no,cancer,lung,adults,11/13/2015
TBD,No,None,daratumumab,JANSSEN BIOTECH,INJECTABLE;INJECTION,,Darzalex,Prescription,N/A; Orphan,100MG/5ML,To treat patients with multiple myeloma who have received at least three prior treatments.,no,no,cancer,blood,adults,11/13/2015
TBD,No,None,daratumumab,JANSSEN BIOTECH,INJECTABLE;INJECTION,,Darzalex,Prescription,N/A; Orphan,400MG/20ML,To treat patients with multiple myeloma who have received at least three prior treatments.,no,no,cancer,blood,adults,11/16/2015
Yes,No,None,ixazomib,MILLENNIUM PHARMS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ninlaro,Prescription,PRIORITY; Orphan,EQ 2.3MG BASE,To treat people with multiple myeloma who have received at least one prior therapy,no,no,cancer,blood,adults,11/16/2015
Yes,No,None,ixazomib,MILLENNIUM PHARMS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ninlaro,Prescription,PRIORITY; Orphan,EQ 3MG BASE,To treat people with multiple myeloma who have received at least one prior therapy,no,no,cancer,blood,adults,11/20/2015
Yes,Yes,None,ixazomib,MILLENNIUM PHARMS,CAPSULE;ORAL,Type 1 - New Molecular Entity,Ninlaro,Prescription,PRIORITY; Orphan,EQ 4MG BASE,To treat people with multiple myeloma who have received at least one prior therapy,no,no,cancer,blood,adults,11/20/2015